

CURRICULUM VITAE

Universitätsprofessor Dr. med. Jan Buer, Dekan

*26. Dezember 1966 in Braunschweig

Privat

Semperstraße 26, 45138 Essen
Email: buer.jan@uk-essen.de

Verheiratet mit Gunda Buer, geb. Ley
Kinder Lara (28) & Felix (24)



Schule

1985 Abitur am Gymnasium Vegesack (Bremen)

Wehrdienst

1985-86 Luftwaffe, Axtstedt (Niedersachsen)

Studium

1987-94 Medizin, Medizinische Hochschule Hannover (MHH), Hannover

Klinischer & wissenschaftlicher Werdegang

1990-95 Promotion in der Abteilung für Hämatologie und Onkologie der MHH (Professor A. Ganser) und am Memorial Sloan-Kettering Cancer Center (Professor J.R. Bertino) in New York mit „summa cum laude“

1995-96 Arzt im Praktikum in der Abteilung für Hämatologie und Onkologie der MHH (Professor A. Ganser)

1996 Approbation als Arzt

1996-98 Postdoktorand bei Professor H. von Boehmer am Hôpital Necker Enfants Malades (INSERM U373) in Paris

1998-03 Leiter der BMBF-Nachwuchsforschungsgruppe „Mukosale Immunität“ im Bereich für Zellbiologie (Professor J. Wehland) bei der Gesellschaft für Biotechnologische Forschung (GBF) in Braunschweig (heute Helmholtz-Zentrum für Infektionsforschung, HZI)

- 1998-03 Weiterbildung zum Facharzt für Medizinische Mikrobiologie am Institut für Medizinische Mikrobiologie und Krankenhaushygiene der MHH
(**Professor D. Bitter-Suermann**)
- 07/2001 **Habilitation für das Fach „Immunologie“** an der MHH und Ernennung zum „Privatdozenten“: „Funktionelle Genomanalyse des T-Zell-Immunsystems: Selektion, Überleben und Regulation“
- 05/2003 **Facharzt** für Medizinische Mikrobiologie, Virologie und Infektionsepidemiologie
- 09/2003 Ernennung zum C3 Professor und Oberarzt, MHH (Brückenprofessur mit dem HZI).
- 02/2004 **Erweiterung der *Venia legendi*** auf das Lehrgebiet „Medizinische Mikrobiologie“, MHH
- 06/2007 W3 Professor für Medizinische Mikrobiologie und Institutsdirektor, Universitätsklinikum Essen & Medizinische Fakultät der Universität Duisburg-Essen**
- 2008-12 Prodekan für Forschung und wissenschaftlichen Nachwuchs
- 2009-12 Associate Editor Journal of Investigative Dermatology
- 2009-12 Schriftführer der Deutschen Gesellschaft f. Hygiene & Mikrobiologie (DGHM)
- 09/2011 Kongresspräsident der 63. Jahrestagung der DGHM in Essen (gemeinsam mit K. Pfeffer)
- 03/2012 Gründungsmitglied der Schule für Translationale Immunologie der Deutschen Gesellschaft für Immunologie
- 2012-20 Fachkollegiat der Deutschen Forschungsgemeinschaft (DFG) für Medizinische Mikrobiologie, Parasitologie, Mykologie & Hygiene, Molekulare Infektionsbiologie (FK 204-03)
- 10/2012 Dekan der Medizinischen Fakultät der Universität Duisburg-Essen & Mitglied im Vorstand des Universitätsklinikums Essen (aktuell in der 4. Amtszeit)**
- 10/2012 Kuratoriumsmitglied der Kulturstiftung Essen, Essen
- 2012-20 Mitglied des Aufsichtsrats des HZI, Braunschweig
- 11/2014 Mitglied des Wissenschaftlichen Beirats TWINCORE, Hannover

2017-21	Vorsitzender des Wissenschaftlichen Beirats des TWINCORE
02/2018	Vizepräsident der DGHM (wiedergewählt 03/2020)
02/2018	Kongresspräsident der 70. Jahrestagung der DGHM in Bochum (gemeinsam mit S. Gatermann und F. Mattner)
10/2019	Vorstandsmitglied "Essen.Gesund.Vernetzt. – Medizinische Gesellschaft e.V.", Essen
11/2019	Mitglied im Wissenschaftlichen Beirat von ZIK-Septomics, Jena
05/2020	Mitglied des Hochschulrats der Medizinischen Hochschule Hannover, Hannover, Niedersachsen
07/2021	Mitglied des Wissenschaftlichen Beirat des Leibniz-Forschungsverbundes INFECTIONS
06/2022	Ausrichtung des ordentlichen Medizinischen Fakultätentags (oMFT) in Essen
07/2022	Mitglied des Senats- und Bewilligungsausschusses für die Graduiertenkollegs der DFG (Berufung zum 01.01.2023)
2022-24	Präsident der Deutschen Gesellschaft für Hygiene und Mikrobiologie (DGHM)
12/2023	Mitglied im Vorstand von MEDECON RUHR (Netzwerk der Gesundheitswirtschaft an der Ruhr)
03/2024	Zweite Amtszeit im Hochschulrat der MHH
01/2025	Mitglied als PI beim Begutachtungstermin des EXE-Clusters „ REASONS: Flussökosysteme im Anthropozän - nachhaltige wissenschaftliche Lösungen“ in Bonn

Preise und Auszeichnungen

1995	Promotionspreis der „Gesellschaft der Freunde der MHH“
1996	2-jähriges Forschungsstipendium der DFG (Paris, F)
2006	Roche Applied Science Innovationspreis „Imagining the Future“
2017	Gastprofessur der Huazhong University of Science & Technology, Wuhan
2021	Fachschaftspreis der Lehre für ausgezeichnete Lehre im Wintersemester

2020/2021 (Fachschaft Medizin)

2023-2025 „Advisory Professorship“ des Union Hospital, Wuhan, China

Forschungsschwerpunkte

Immunregulation bei chronischen Infektionen und Krebs

Mikrobiom

Antibiotikaresistenzen

Neuroinfektion und -immunologie

Kardioimmunologie

Klinische Schwerpunkte

Molekulare Diagnostik und opportunistische Pilz-Infektionen mit multi-resistenten Erregern

Impfen und Reisemedizin

Sepsis und Antibiotic-Stewardship

KI, Digitalisierung und Krankenhaushygiene (SMART Hospital)

GREEN Hospital

Weitere Aktivitäten als Institutsdirektor

In der Ärztekammer Nordrhein beschäftige ich mich seit vielen Jahren mit der Weiterbildungsordnung und fungiere regelmäßig als Facharztprüfer für Medizinische Mikrobiologie, Virologie und Infektionsepidemiologie.

Vier meiner Fachärzt:innen haben inzwischen Lehrstühle an Universitätskliniken in Deutschland übernommen (Prof. Jörg Timm, Düsseldorf, Prof. H. Streeck, Bonn, Prof. Jörg Steinmann, Nürnberg und Prof. Sandra Ciesek, Frankfurt)

Drei meiner wissenschaftlichen Mitarbeiter:innen haben ebenfalls Universitätsprofessuren inne (Prof. Dunja Bruder in Magdeburg und Prof. Wiebke Hansen bzw. Prof. Astrid Westendorf (beide Essen) haben ebenfalls inzwischen Lehrstühle inne.

Meine langjährige Mentee Prof. Astrid Westendorf wurde in 04/2023 zur Prorektorin für Forschung und wissenschaftlichen Nachwuchs der Universität Duisburg-Essen gewählt.

Drittmittel (seit 2007)

Gesamt >10 Mio. Euro. Meine Forschung und die meines Instituts wird regelmäßig von der DFG, dem BMBF und der Deutschen Krebshilfe im Normalverfahren unterstützt

Prof. Dr. Astrid Westendorf aus meinem Institut war Sprecherin des DFG GRK1949 „Immunantwort in Infektionskrankheiten - Regulation zwischen angeborener und erworbener Immunität“.

Ich bin außerdem regelmäßig als Teilprojektleiter an verschiedenen Verbundprojekten der DFG beteiligt (TRR60, GRK1431 & GRK2098 & unser Institut an der FOR2879 & GRK2989).

Ich bin Gründungsmitglied im Deutschen Konsortium für Translationale Krebsforschung Standort Essen (DKTK) und im Comprehensive Cancer Center Essen (Exzellenzzentrum der Deutschen Krebshilfe).

Ich bin regelmäßig als Fachkollegiat für die DFG bei der Einrichtung und Begutachtung aller Verbundprojektformate tätig sowie bei Schwerpunktprogrammen, der Afrika-Initiative der DFG, der Exzellenzinitiative und dem Wissenschaftsrat.

Beteiligt am Aufbau des ersten von der DFG geförderten Deutsch-Chinesischen Transregios (TRR60) mit Wuhan in der Medizin (2009-2018).

Gemeinsam mit der Universität Münster bauen wir das „Westdeutsche Infektionspräventionsnetzwerk zur KI-basierten Antibiotikaresistenzdetektion (WIN-KID)“ auf, das von der Landesregierung NRW über die EFRE Innovationsagentur gefördert wird (2021-2027).

Ausgewählte Publikationen als Institutsdirektor in Essen*

Insgesamt über 330 Publikationen mit ca. 20.000 Zitationen, **H-factor 73 (Web-of-Science 2025)*

1. Steinbach, P., Pastille, E., Kaumanns, L., Adamczyk, A., Sutter, K., Hansen, W., Dittmer, U., Buer, J., Westendorf, A.M., and Knuschke, T. (2024). Influenza virus infection enhances tumour-specific CD8+ T-cell immunity, facilitating tumour control. *PLoS Pathog* 20, e1011982. 10.1371/journal.ppat.1011982.
2. Huang, K.D., Amend, L., Galvez, E.J., Lesker, T.R., de Oliveira, R., Bielecka, A., Blanco-Miguez, A., Valles-Colomer, M., Ruf, I., Pasolli, E., Buer, J., Segata, N., Esser, S., Strowig, T., and Kehrman, J. (2024). Establishment of a non-Westernized gut microbiota in MSM is associated with sexual practices *Cell Reports Medicine*.
3. Kehrman, J., Koch, F., Zumdick, S., Howner, A., Best, L., Masshofer, L., Scharfenberg, S., Zeschneig, M., Becker, J.C., Schadendorf, D., Buer, J., and Roesch, A. (2023). Reduced *Staphylococcus* Abundance Characterizes the Lesional Microbiome of Actinic Keratosis Patients after Field-Directed Therapies. *Microbiol Spectr* 11, e0440122. 10.1128/spectrum.04401-22.
4. Abberger, H., Hose, M., Ninnemann, A., Menne, C., Eilbrecht, M., Lang, K.S., Matuschewski, K., Geffers, R., Herz, J., Buer, J., Westendorf, A.M., and Hansen, W. (2023). Neuropilin-1 identifies a subset of highly activated CD8+ T cells during parasitic and viral infections. *PLoS Pathog* 19, e1011837. 10.1371/journal.ppat.1011837.

5. Zeng, N., Capelle, C.M., Baron, A., Kobayashi, T., Cire, S., Tslaf, V., Leonard, C., Coowar, D., Koseki, H., Westendorf, A.M., Buer, J., Brenner, D., Krüger, R., Balling, R., Ollert, M., and Hefeng, F.Q. (2022). DJ-1 depletion prevents immunoaging in T-cell compartments. *EMBO reports*. 10.15252/embr.202153302.
6. Pylaeva, E., Korschunow, G., Spyra, I., Bordbari, S., Siakaeva, E., Ozel, I., Domnich, M., Squire, A., Hasenberg, A., Thangavelu, K., Hussain, T., Goetz, M., Lang, K.S., Gunzer, M., Hansen, W., Buer, J., Bankfalvi, A., Lang, S., and Jablonska, J. (2022). During early stages of cancer, neutrophils initiate anti-tumor immune responses in tumor-draining lymph nodes. *Cell Rep* 40, 111171. 10.1016/j.celrep.2022.111171.
7. Hose, M., Gunther, A., Naser, E., Schumacher, F., Schonberger, T., Falkenstein, J., Papadamakis, A., Kleuser, B., Becker, K.A., Gulbins, E., Haimovitz-Friedman, A., Buer, J., Westendorf, A.M., and Hansen, W. (2022). Cell-intrinsic ceramides determine T cell function during melanoma progression. *Elife* 11. 10.7554/eLife.83073.
8. Gunther, A., Hose, M., Abberger, H., Schumacher, F., Veith, Y., Kleuser, B., Matuschewski, K., Lang, K.S., Gulbins, E., Buer, J., Westendorf, A., and Hansen, W. (2022). The acid ceramidase/ceramide axis controls parasitemia in *Plasmodium yoelii*-infected mice by regulating erythropoiesis. *Elife* 11. 10.7554/eLife.77975.
9. Palmieri, V., Ebel, J.F., Ngo Thi Phuong, N., Klopffleisch, R., Vu, V.P., Adamczyk, A., Zoller, J., Riedel, C., Buer, J., Krebs, P., Hansen, W., Pastille, E., and Westendorf, A.M. (2021). Interleukin-33 signaling exacerbates experimental infectious colitis by enhancing gut permeability and inhibiting protective Th17 immunity. *Mucosal Immunol*. 10.1038/s41385-021-00386-7.
10. Adamczyk, A., Pastille, E., Kehrmann, J., Vu, V.P., Geffers, R., Wasmer, M.H., Kasper, S., Schuler, M., Lange, C.M., Muggli, B., Rau, T.T., Klein, D., Hansen, W., Krebs, P., Buer, J., and Westendorf, A.M. (2021). GPR15 facilitates recruitment of regulatory T cells to promote colorectal cancer. *Cancer Res*. 10.1158/0008-5472.CAN-20-2133.
11. Choudhury, A.R., Ju, Z.Y., Djojosebroto, M.W., Schienke, A., Lechel, A., Schaetzlein, S., Jiang, H., Stepczynska, A., Wang, C.F., Buer, J., Lee, H.W., von Zglinicki, T., Ganser, A., Schirmacher, P., Nakauchi, H., and Rudolph, K.L. (2020). Cdkn1a deletion improves stem cell function and lifespan of mice with dysfunctional telomeres without accelerating cancer formation (vol 39, pg 99, 2007). *Nat Genet* 52, 548-548. 10.1038/s41588-020-0593-6.
12. Pastille, E., Wasmer, M.H., Adamczyk, A., Vu, V.P., Mager, L.F., Phuong, N.N.T., Palmieri, V., Simillion, C., Hansen, W., Kasper, S., Schuler, M., Muggli, B., McCoy, K.D., Buer, J., Zlobec, I., Westendorf, A.M., and Krebs, P. (2019). The IL-33/ST2 pathway shapes the regulatory T cell phenotype to promote intestinal cancer. *Mucosal Immunol*. 10.1038/s41385-019-0176-y.
13. Robak, O.H., Heimesaat, M.M., Kruglov, A.A., Prepens, S., Ninnemann, J., Gutbier, B., Reppe, K., Hochrein, H., Suter, M., Kirschning, C.J., Marathe, V., Buer, J., Hornef, M.W., Schnare, M., Schneider, P., Witzernath, M., Bereswill, S., Steinhoff, U., Suttrop, N., Sander, L.E., Chaput, C., and Opitz, B. (2018). Antibiotic treatment-induced secondary IgA deficiency enhances susceptibility to *Pseudomonas aeruginosa* pneumonia. *J Clin Invest* 128, 3535-3545. 10.1172/JCI97065.
14. Klein, J.C., Moses, K., Zelinsky, G., Sody, S., Buer, J., Lang, S., Helfrich, I., Dittmer, U., Kirschning, C.J., and Brandau, S. (2017). Combined toll-like receptor 3/7/9 deficiency on host cells results in T-cell-dependent control of tumour growth. *Nat Commun* 8, 14600. 10.1038/ncomms14600.
15. Adamczyk, A., Gageik, D., Frede, A., Pastille, E., Hansen, W., Rueffer, A., Buer, J., Buning, J., Langhorst, J., and Westendorf, A.M. (2017). Differential expression of GPR15 on T cells during ulcerative colitis. *JCI Insight* 2. 10.1172/jci.insight.90585.
16. Wadwa, M., Klopffleisch, R., Adamczyk, A., Frede, A., Pastille, E., Mahnke, K., Hansen, W., Geffers, R., Lang, K.S., Buer, J., Buning, J., and Westendorf, A.M. (2016). IL-10 downregulates

- CXCR3 expression on Th1 cells and interferes with their migration to intestinal inflammatory sites. *Mucosal Immunol* 9, 1263-1277. 10.1038/mi.2015.132.
17. Kruger, A., Oldenburg, M., Chebrolu, C., Beisser, D., Kolter, J., Sigmund, A.M., Steinmann, J., Schafer, S., Hochrein, H., Rahmann, S., Wagner, H., Henneke, P., Hornung, V., Buer, J., and Kirschning, C.J. (2015). Human TLR8 senses UR/URR motifs in bacterial and mitochondrial RNA. *EMBO Rep* 16, 1656-1663. 10.15252/embr.201540861.
 18. Pastille, E., Bardini, K., Fleissner, D., Adamczyk, A., Frede, A., Wadwa, M., von Smolinski, D., Kasper, S., Sparwasser, T., Gruber, A.D., Schuler, M., Sakaguchi, S., Roers, A., Muller, W., Hansen, W., Buer, J., and Westendorf, A.M. (2014). Transient ablation of regulatory T cells improves antitumor immunity in colitis-associated colon cancer. *Cancer Res* 74, 4258-4269. 10.1158/0008-5472.CAN-13-3065.
 19. Riss, G.L., Chang, D.I., Wevers, C., Westendorf, A.M., Buer, J., Scherbaum, N., and Hansen, W. (2012). Opioid maintenance therapy restores CD4+ T cell function by normalizing CD4+CD25(high) regulatory T cell frequencies in heroin user. *Brain Behav Immun* 26, 972-978. 10.1016/j.bbi.2012.05.008.
 20. Oldenburg, M., Kruger, A., Ferstl, R., Kaufmann, A., Nees, G., Sigmund, A., Bathke, B., Lauterbach, H., Suter, M., Dreher, S., Koedel, U., Akira, S., Kawai, T., Buer, J., Wagner, H., Bauer, S., Hochrein, H., and Kirschning, C.J. (2012). TLR13 recognizes bacterial 23S rRNA devoid of erythromycin resistance-forming modification. *Science* 337, 1111-1115. 10.1126/science.1220363.
 21. Hansen, W., Hutzler, M., Abel, S., Alter, C., Stockmann, C., Kliche, S., Albert, J., Sparwasser, T., Sakaguchi, S., Westendorf, A.M., Schadendorf, D., Buer, J., and Helfrich, I. (2012). Neuropilin 1 deficiency on CD4+Foxp3+ regulatory T cells impairs mouse melanoma growth. *J Exp Med* 209, 2001-2016. 10.1084/jem.20111497.
 22. Schenk, U., Frascoli, M., Proietti, M., Geffers, R., Traggiai, E., Buer, J., Ricordi, C., Westendorf, A.M., and Grassi, F. (2011). ATP inhibits the generation and function of regulatory T cells through the activation of purinergic P2X receptors. *Sci Signal* 4, ra12. 10.1126/scisignal.2001270.
 23. Sokolova, V., Knuschke, T., Kovtun, A., Buer, J., Eppele, M., and Westendorf, A.M. (2010). The use of calcium phosphate nanoparticles encapsulating Toll-like receptor ligands and the antigen hemagglutinin to induce dendritic cell maturation and T cell activation. *Biomaterials* 31, 5627-5633. 10.1016/j.biomaterials.2010.03.067.
 24. Bar-On, L., Birnberg, T., Lewis, K.L., Edelson, B.T., Bruder, D., Hildner, K., Buer, J., Murphy, K.M., Reizis, B., and Jung, S. (2010). CX3CR1+ CD8alpha+ dendritic cells are a steady-state population related to plasmacytoid dendritic cells. *Proc Natl Acad Sci U S A* 107, 14745-14750. 10.1073/pnas.1001562107.
 25. Westendorf, A.M., Fleissner, D., Groebe, L., Jung, S., Gruber, A.D., Hansen, W., and Buer, J. (2009). CD4+Foxp3+ regulatory T cell expansion induced by antigen-driven interaction with intestinal epithelial cells independent of local dendritic cells. *Gut* 58, 211-219. 10.1136/gut.2008.151720.
 26. TrehanPati, N., Geffers, R., Sukriti, Hissar, S., Riese, P., Toepfer, T., Buer, J., Kumar, M., Guzman, C.A., and Sarin, S.K. (2009). Gene expression signatures of peripheral CD4+ T cells clearly discriminate between patients with acute and chronic hepatitis B infection. *Hepatology* 49, 781-790. 10.1002/hep.22696.
 27. Gereke, M., Jung, S., Buer, J., and Bruder, D. (2009). Alveolar type II epithelial cells present antigen to CD4(+) T cells and induce Foxp3(+) regulatory T cells. *Am J Respir Crit Care Med* 179, 344-355. 10.1164/rccm.200804-592OC.

28. Veldhoen, M., Uyttenhove, C., van Snick, J., Helmby, H., Westendorf, A., Buer, J., Martin, B., Wilhelm, C., and Stockinger, B. (2008). Transforming growth factor-beta 'reprograms' the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset. *Nat Immunol* 9, 1341-1346. 10.1038/ni.1659.
29. Veldhoen, M., Hirota, K., Westendorf, A.M., Buer, J., Dumoutier, L., Renauld, J.C., and Stockinger, B. (2008). The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins. *Nature* 453, 106-109. 10.1038/nature06881.
30. Schenk, U., Westendorf, A.M., Radaelli, E., Casati, A., Ferro, M., Fumagalli, M., Verderio, C., Buer, J., Scanziani, E., and Grassi, F. (2008). Purinergic control of T cell activation by ATP released through pannexin-1 hemichannels. *Sci Signal* 1, ra6. 10.1126/scisignal.1160583.
31. Nickeleit, I., Zender, S., Sasse, F., Geffers, R., Brandes, G., Sorensen, I., Steinmetz, H., Kubicka, S., Carlomagno, T., Menche, D., Gutgemann, I., Buer, J., Gossler, A., Manns, M.P., Kalesse, M., Frank, R., and Malek, N.P. (2008). Argyrin a reveals a critical role for the tumor suppressor protein p27(kip1) in mediating antitumor activities in response to proteasome inhibition. *Cancer Cell* 14, 23-35. 10.1016/j.ccr.2008.05.016.
32. Haile, L.A., von Waselewski, R., Gamrekashvili, J., Kruger, C., Bachmann, O., Westendorf, A.M., Buer, J., Liblau, R., Manns, M.P., Korangy, F., and Greten, T.F. (2008). Myeloid-derived suppressor cells in inflammatory bowel disease: a new immunoregulatory pathway. *Gastroenterology* 135, 871-881, 881 e871-875. 10.1053/j.gastro.2008.06.032.
33. Stecher, B., Robbiani, R., Walker, A.W., Westendorf, A.M., Barthel, M., Kremer, M., Chaffron, S., Macpherson, A.J., Buer, J., Parkhill, J., Dougan, G., von Mering, C., and Hardt, W.D. (2007). *Salmonella enterica* serovar typhimurium exploits inflammation to compete with the intestinal microbiota. *PLoS Biol* 5, 2177-2189. 10.1371/journal.pbio.0050244.
34. Choudhury, A.R., Ju, Z., Djojosebroto, M.W., Schienke, A., Lechel, A., Schaetzlein, S., Jiang, H., Stepczynska, A., Wang, C., Buer, J., Lee, H.W., von Zglinicki, T., Ganser, A., Schirmacher, P., Nakauchi, H., and Rudolph, K.L. (2007). Cdkn1a deletion improves stem cell function and lifespan of mice with dysfunctional telomeres without accelerating cancer formation. *Nat Genet* 39, 99-105. 10.1038/ng1937.
35. Bohn, G., Allroth, A., Brandes, G., Thiel, J., Glocker, E., Schaffer, A.A., Rathinam, C., Taub, N., Teis, D., Zeidler, C., Dewey, R.A., Geffers, R., Buer, J., Huber, L.A., Welte, K., Grimbacher, B., and Klein, C. (2007). A novel human primary immunodeficiency syndrome caused by deficiency of the endosomal adaptor protein p14. *Nat Med* 13, 38-45. 10.1038/nm1528.

Organisation und Management Tätigkeit als Dekan & Vorstandsmitglied (Auswahl)

Erfolgreiche Durchführung der Begutachtung der Universitätsmedizin Essen durch den Wissenschaftsrat (WR) (11/2018).

Ca. 100 erfolgreich abgeschlossene Berufungsverfahren (Anteil Frauen in diesem Zeitraum deutlich über dem Bundesdurchschnitt in der Medizin).

Nachwuchsförderung (UMEA & UMEA^{2*}, ELAN, BIOME-Graduiertenschule, Forschungstag, Winterseminar) mit eigenem Prodekanat für Akademische Karriereentwicklung und Diversität (*Clinician Scientist Programm der DFG bewilligt 2018 und Advanced Clinician Scientist Programm aktuell bewilligt vom BMBF).

Durchführung strategischer Maßnahmen im Hinblick auf die neue Approbationsordnung.

Aufbau eines Wissenschaftscurriculums im Studium.

Eröffnung des Lehr-und Lernzentrums mit Deichmann Auditorium, SkillsLab und SimArena.

Eröffnung des Medizinischen Forschungszentrums mit IMCES-Imaging Center Essen.

Etablierung des „Cancer Research Center Cologne Essen“ (2019) und Bewerbung der Medizinischen Fakultäten der Universität Duisburg-Essen und der Universität zu Köln als Auswahl für die Konzeptentwicklungsphase der BMBF Ausschreibung NCT-Erweiterung (2020/2021) mit Start des Neubaus Tumorzentrum-West. Erfolgreicher Start des neuen NCT-West in 2023.

Eröffnung des Westdeutschen Protonentherapiezentrum Essen (2013).

Aufbau einer starken Allgemeinmedizin mit großem Netz an Lehrpraxen (>200).

Etablierung des ersten W3-Lehrstuhls für Allgemeinmedizin (W3-Ruf angenommen 04/2020).

Etablierung einer gemeinsamen Klinik für Hämatologie und Stammzelltransplantation (W3-Ruf angenommen 4/2020).

Aufbau NAKO-Studienzentrum Essen (Startschuss der NAKO durch Ministerinnen Svenja Schulze und Johanna Wanka in Essen 2014).

Aufbau eines Referats für Strategie, Kommunikation und Marketing.

Durchführung der Festveranstaltung zum 50-jährigen Jubiläum der Medizinischen Fakultät Essen in der Philharmonie Essen (2013) und zum 60-jährigen Jubiläum mit Sabine Heinrich vom WDR (Juni 2023).

Verleihung der Meyer-Schwickerath-Medaille an Frank-Walter Steinmeier, Bundesaußenminister a.D. (2015).

Verleihung der Ehrenpromotion an Ottmar Wiestler, Berlin (2016) und Alexander MM Eggermont, Paris (2018).

Eröffnung des Westdeutschen Herz und Gefäßzentrums durch Hermann Gröhe, Bundesgesundheitsminister a.D. (2015).

Etablierung der Westdeutschen Biobank Essen (2013).

Aufbau und Verlängerung des DFG GRK 1739 „Molekulare Determinanten der zellulären Strahlenantwort und ihre Bedeutung für die Modulation der Strahlensensitivität“.

Aufbau und Verlängerung des DFG GRK 1949 „Immunantwort in Infektionskrankheiten - Regulation zwischen angeborener und erworbener Immunität“.

Aufbau des DFG GRK 2098 „Biomedicine of Sphingolipids“.

Aufbau der DFG KFO 337 „Phänotypische Therapie- und Immunresistenz in Krebs (PhenoTImE)“ – zur Verlängerung empfohlen.

Aufbau der DFG FOR 2879 „From immune cells to stroke recovery (IMMUNOSTROKE)“ gemeinsam mit UKE (Hamburg), Uniklinikum (Münster) und LMU (München).

Aufbau von aktuell zwei federführenden SFB-/TRR-Initiativen der medizinischen Fakultät SFB/TRR 289 „Treatment Expectation“ (2020) und SFB/TRR 296 „Local Control of Thyroid Hormone Action (LOCOTACT)“ (2020).

Aufbau einer starken regionalen Vernetzung mit der Ruhr-Universität Bochum (SFB1116), dem Universitätsklinikum Düsseldorf (SFB 1280) und dem Leibniz-Institut für Analytische Wissenschaften – ISAS in Dortmund (gemeinsame Brückenprofessuren).

2020 wurde das Institut für Urbane Öffentliche Gesundheit (InUPH) unter Leitung von Prof. Susanne Moebus gegründet. Sie ist Co-Vorsitzende des Expertengremiums für „Gesundheit und Resilienz“ im Bundeskanzleramt.

Aufbau des GRK 2535: "Wissens- und datenbasierte Personalisierung von Medizin am Point of Care" gemeinsam mit der Fachhochschule Dortmund, Medizinische Informatik), Förderungszeitraum: seit 2021.

Seit März 2018 ist die Universitätsmedizin Essen dem Medizininformatik-Verbund beigetreten (SMITH-Konsortium). Mein besonderes Interesse gilt hierbei der Verbesserung der Sepsisdiagnostik.

Gemeinsame Investitionen von Fakultät und Uniklinikum in Medizinische Informatik, Digitalisierung und KI (neu geschaffenes Institut für KI in der Medizin mit bereits sieben erfolgreich berufenen W3 Professuren, fünf Nachwuchsgruppen und ca. 145 Mitarbeitenden).

Grundsteinlegung für den Neubau der Klinik für seltene Erkrankungen am Standort Ruhrlandklinik der Universitätsmedizin Essen durch NRW-Gesundheitsminister Karl-Josef Laumann (2021) und Ausbau des Lungentransplantationsschwerpunktes. Eröffnung der neuen Klinik durch Minister Laumann am 17.01.2024.

Erfolgreiche Beteiligung der Universitätsmedizin Essen im Bereich Onkologie und Neurowissenschaften in der Research Alliance Ruhr – One Health des Landes NRW.

Beteiligung am neu eingerichteten SFB 1430 „Molekulare Mechanismen von Zellzustandsübergängen“ am gemeinsamen Zentrum für Medizinische Biotechnologie der Universität Duisburg-Essen (05/2021).

Beteiligung am SFB/TRR 332: "Neutrophile Granulozyten: Entwicklung, Verhalten, und Funktion" mit Uni Münster und LMU München seit 2022.

Als Dekan und langjähriges Vorstandsmitglied bin ich am Uniklinik-Standort Essen für die Durchführung des Medizinischen Modernisierungsprogramms (MedMoP) des Landes NRW mitverantwortlich. Hierbei wurden in Essen innerhalb von fünf Jahren (bis Ende 2022) rund 300 Millionen Euro für sechs Bau- und Sanierungsprojekte investiert. Dies beinhaltet den Neubau der HNO-Augenheilkunde (abgeschlossen in 2021), Nuklearmedizin, Kinderklinik und Pathologie-/Rechtsmedizin.

Gemeinsam entwickeln wir in Essen im Dekanat und Vorstand das Uniklinikum zum „Smart Hospital“ weiter. Beispiele sind KI in der Röntgendiagnostik (gemeinsam mit Prof. Michael Forsting und Prof. Felix Nensa) oder die erfolgreiche Einführung der elektronischen Patientenakte mit unserer zentralen IT.

International habe ich die Fakultät intensiv vernetzt mit Partneruniversitäten in China, Ukraine, Mongolei, Kuba, Mexico, Costa Rica, Japan und USA.

Im Dezember 2023 hat die DFG ein weiteres GRK 2989: „Targeting Cellular Interfaces in Reperfused Acute Myocardial Infarction (TCI repAMI)“ für 4 Jahre bewilligt.

Am Standort Essen koordiniere ich als Dekan die Aktivitäten der Medizinischen Fakultät im Rahmen der nächsten Runde der Exzellenz-Initiative der Universität Duisburg-Essen und beteilige mich als PI an der Cluster Initiative REASON - Flussökosysteme im Anthropozän, der gerade im Januar in Bonn begutachtet wurde.



Essen, den 14. Februar 2025

Prof. Dr. med. Jan Buer

Jan Buer on ORCID

<https://orcid.org/0000-0002-7602-1698>

Wissenschaftliche Veröffentlichungen Jan Buer

1. Mekes-Adamczyk, A., Gausmann, N., Oznur, O., Pfuhlmann, K., Dziobaka, J., Buer, J., Langhorst, J., and Westendorf, A.M. (2025). Lifestyle Intervention Modulates the CD4⁺ T Cell Profile in the Blood of Crohn's Disease Patients. *Inflamm Bowel Dis* 31, 200-209. 10.1093/ibd/izae154.
2. Vogel, L.H., Kampf, J., Dykun, I., Mahmoud, I., Rath, P.-M., Buer, J., Rassaf, T., and Mahabadi, A.A. (2024). Artificial intelligence and logistic regression vs. the modified Duke score in the detection of infective endocarditis: a comparison within the PRO-ENDOCARDITIS study. *Journal of Medical Artificial Intelligence* 7, 24-24. 10.21037/jmai-23-169.
3. Steinbach, P., Pastille, E., Kaumanns, L., Adamczyk, A., Sutter, K., Hansen, W., Dittmer, U., Buer, J., Westendorf, A.M., and Knuschke, T. (2024). Influenza virus infection enhances tumour-specific CD8⁺ T-cell immunity, facilitating tumour control. *PLoS Pathog* 20, e1011982. 10.1371/journal.ppat.1011982.
4. Mekes-Adamczyk, A., Gausmann, N., Oznur, O., Pfuhlmann, K., Dziobaka, J., Buer, J., Langhorst, J., and Westendorf, A.M. (2024). Lifestyle Intervention Modulates the CD4⁺ T Cell Profile in the Blood of Crohn's Disease Patients. *Inflamm Bowel Dis*. 10.1093/ibd/izae154.
5. Lechel, A., Ande, S., Ju, Z., Plentz, R.R., Schaetzlein, S., Rudolph, C., Wilkens, L., Wiemann, S.U., Saretzki, G., Malek, N.P., Manns, M.P., Buer, J., and Rudolph, K.L. (2024). Author Correction: The cellular level of telomere dysfunction determines induction of senescence or apoptosis in vivo. *EMBO Rep* 25, 3738. 10.1038/s44319-024-00192-9.
6. Kirchhoff, L., Arweiler-Harbeck, D., Meyer, M., Buer, J., Lang, S., Steinmann, J., Bertram, R., Deuss, E., and Hoing, B. (2024). Bacterial biofilm formation on headpieces of Cochlear implants. *Eur Arch Otorhinolaryngol*. 10.1007/s00405-024-08835-2.
7. Kehrmann, J., Stumpf, A.L., Dragaqina, A., and Buer, J. (2024). Improved detection of mycobacteria in CF and tissue samples grown in mycobacteria growth indicator tube incubated at 30 degrees C compared to conventional growth conditions of liquid and solid media. *J Clin Microbiol* 62, e0068324. 10.1128/jcm.00683-24.
8. Huang, K.D., Amend, L., Galvez, E.J.C., Lesker, T.R., de Oliveira, R., Bielecka, A., Blanco-Miguez, A., Valles-Colomer, M., Ruf, I., Pasolli, E., Buer, J., Segata, N., Esser, S., Strowig, T., and Kehrmann, J. (2024). Establishment of a non-Westernized gut microbiota in men who have sex with men is associated with sexual practices. *Cell Rep Med* 5, 101426. 10.1016/j.xcrm.2024.101426.
9. Dyckhoff-Shen, S., Masouris, I., Islam, H., Hammerschmidt, S., Angele, B., Marathe, V., Buer, J., Volk, S., Pfister, H.W., Klein, M., Koedel, U., and Kirschning, C.J. (2024). Combining antibiotic with anti-TLR2/TLR13 therapy prevents brain pathology in pneumococcal meningitis. *JCI Insight*. 10.1172/jci.insight.165737.
10. Brehmer, A., Sauer, C.M., Salazar Rodriguez, J., Herrmann, K., Kim, M., Keyl, J., Bahnsen, F.H., Frank, B., Koehrmann, M., Rassaf, T., Mahabadi, A.A., Hadaschik, B., Darr, C., Herrmann, K., Tan, S., Buer, J., Brenner, T., Reinhardt, H.C., Nensa, F., Gertz, M., Egger, J., and Kleesiek, J. (2024). Establishing Medical Intelligence - Leveraging FHIR to Improve Clinical Management: a retrospective cohort and clinical implementation study. *J Med Internet Res*. 10.2196/55148.
11. Beltsios, E., Zubarevich, A., Ruemke, S., Rubalskii, E., Osswald, A., Arjomandi Rad, A., Heidenau, F., Buer, J., Hanke, J., Schmitto, J., Popov, A.F., Kuehn, C., Schmack, B., Ruhparwar,

- A., and Weymann, A. (2024). Antibacterial copper-filled TiO₂ coating of cardiovascular implants to prevent infective endocarditis-A pilot study. *Artif Organs* 48, 356-364. 10.1111/aor.14688.
12. Verhasselt, H.L., Ramakrishnan, E., Schlag, M., Marchesi, J.R., Buer, J., Kleinschnitz, C., Hagenacker, T., and Totzeck, A. (2023). Fungal Gut Microbiome in Myasthenia Gravis: A Sub-Analysis of the MYBIOM Study. *J Fungi (Basel)* 9. 10.3390/jof9050569.
13. Sokolova, V., Loza, K., Ebel, J.F., Buer, J., Westendorf, A.M., and Epple, M. (2023). Barium sulphate microparticles are taken up by three different cell types: HeLa, THP-1, and hMSC. *Acta Biomater* 164, 577-587. 10.1016/j.actbio.2023.03.043.
14. Mardiko, A.A., Buer, J., Koster, A.M., Kaba, H.E.J., Mattner, F., Zweigner, J., Mutters, N.T., von Maltzahn, N., Leistner, R., Eckmanns, T., Brandt, C., and Scheithauer, S. (2023). Infection prevention and control between legal requirements and German Society for Hygiene and Microbiology expert assessments: a cross-sectional study in September-November 2022. *J Hosp Infect* 137, 35-43. 10.1016/j.jhin.2023.04.001.
15. Mahabadi, A.A., Mincu, R., Dykun, I., Michel, L., Kung, A., Witzke, O., Kill, C., Buer, J., Rassaf, T., and Totzeck, M. (2023). Frequency and prognosis of CVD and myocardial injury in patients presenting with suspected COVID-19 - The CoV-COR registry. *Int J Cardiol Heart Vasc* 45, 101184. 10.1016/j.ijcha.2023.101184.
16. Madel, R.J., Borger, V., Dittrich, R., Bremer, M., Tertel, T., Phuong, N.N.T., Baba, H.A., Kordelas, L., Staubach, S., Stein, F., Haberkant, P., Hackl, M., Grillari, R., Grillari, J., Buer, J., Horn, P.A., Westendorf, A.M., Brandau, S., Kirschning, C.J., and Giebel, B. (2023). Independent human mesenchymal stromal cell-derived extracellular vesicle preparations differentially attenuate symptoms in an advanced murine graft-versus-host disease model. *Cytotherapy* 25, 821-836. 10.1016/j.jcyt.2023.03.008.
17. Kehrmann, J., Koch, F., Zumdick, S., Howner, A., Best, L., Maschofer, L., Scharfenberg, S., Zeschning, M., Becker, J.C., Schadendorf, D., Buer, J., and Roesch, A. (2023). Reduced *Staphylococcus* Abundance Characterizes the Lesional Microbiome of Actinic Keratosis Patients after Field-Directed Therapies. *Microbiol Spectr* 11, e0440122. 10.1128/spectrum.04401-22.
18. Haj-Yehia, E., Korste, S., Jochem, R., Lusha, A., Roth, A., Dietzel, N., Niroomand, J., Stock, P., Westendorf, A.M., Buer, J., Hendgen-Cotta, U.B., Rassaf, T., and Totzeck, M. (2023). CD47 blockade enhances phagocytosis of cardiac cell debris by neutrophils. *Int J Cardiol Heart Vasc* 48, 101269. 10.1016/j.ijcha.2023.101269.
19. Buys, W., Bick, A., Madel, R.J., Westendorf, A.M., Buer, J., Herbstreit, F., Kirschning, C.J., and Peters, J. (2023). Substantial heterogeneity of inflammatory cytokine production and its inhibition by a triple cocktail of toll-like receptor blockers in early sepsis. *Front Immunol* 14, 1277033. 10.3389/fimmu.2023.1277033.
20. Abberger, H., Hose, M., Ninnemann, A., Menne, C., Eilbrecht, M., Lang, K.S., Matuschewski, K., Geffers, R., Herz, J., Buer, J., Westendorf, A.M., and Hansen, W. (2023). Neuropilin-1 identifies a subset of highly activated CD8⁺ T cells during parasitic and viral infections. *PLoS Pathog* 19, e1011837. 10.1371/journal.ppat.1011837.
21. Zeng, N., Capelle, C.M., Baron, A., Kobayashi, T., Cire, S., Tslaf, V., Leonard, C., Coowar, D., Koseki, H., Westendorf, A.M., Buer, J., Brenner, D., Krüger, R., Balling, R., Ollert, M., and Hefeng, F.Q. (2022). DJ-1 depletion prevents immunoaging in T-cell compartments. *EMBO reports*. 10.15252/embr.202153302.

22. Wilk, C., Effenberg, L., Abberger, H., Steenpass, L., Hansen, W., Zeschnigk, M., Kirschning, C., Buer, J., and Kehrmann, J. (2022). CRISPR/Cas9-mediated demethylation of FOXP3-TSDR toward Treg-characteristic programming of Jurkat T cells. *Cell Immunol* 371, 104471. 10.1016/j.cellimm.2021.104471.
23. Wenzek, C., Steinbach, P., Wirsdorfer, F., Sutter, K., Boehme, J.D., Geffers, R., Klopffleisch, R., Bruder, D., Jendrossek, V., Buer, J., Westendorf, A.M., and Knuschke, T. (2022). CD47 restricts antiviral function of alveolar macrophages during influenza virus infection. *iScience* 25, 105540. 10.1016/j.isci.2022.105540.
24. Schildhaus, H.U., Steindor, M., Kolsch, B., Herold, T., Buer, J., and Kehrmann, J. (2022). GenoType CM Direct((R)) and VisionArray Myco((R)) for the Rapid Identification of Mycobacteria from Clinical Specimens. *J Clin Med* 11. 10.3390/jcm11092404.
25. Scharmann, U., Herbstreit, F., Steckel, N.K., Dedy, J., Buer, J., Rath, P.M., and Verhasselt, H.L. (2022). Prevalence of COVID-19 Associated Mucormycosis in a German Tertiary Care Hospital. *J Fungi (Basel)* 8. 10.3390/jof8030307.
26. Sanders, M.I., Ali, E., Buer, J., Steinmann, J., Rath, P.-M., Verhasselt, H.L., and Kirchhoff, L. (2022). Antibacterial Activity of the Novel Drug Gepotidacin against *Stenotrophomonas maltophilia*—An In Vitro and In Vivo Study. *Antibiotics* 11. 10.3390/antibiotics11020192.
27. Reinold, J., Farahpour, F., Schoerding, A.K., Fehring, C., Dolff, S., Konik, M., Korth, J., van Baal, L., Buer, J., Witzke, O., Westendorf, A.M., and Kehrmann, J. (2022). The Fungal Gut Microbiome Exhibits Reduced Diversity and Increased Relative Abundance of Ascomycota in Severe COVID-19 Illness and Distinct Interconnected Communities in SARS-CoV-2 Positive Patients. *Front Cell Infect Microbiol* 12, 848650. 10.3389/fcimb.2022.848650.
28. Pylaeva, E., Korschunow, G., Spyra, I., Bordbari, S., Siakaeva, E., Ozel, I., Domnich, M., Squire, A., Hasenberg, A., Thangavelu, K., Hussain, T., Goetz, M., Lang, K.S., Gunzer, M., Hansen, W., Buer, J., Bankfalvi, A., Lang, S., and Jablonska, J. (2022). During early stages of cancer, neutrophils initiate anti-tumor immune responses in tumor-draining lymph nodes. *Cell Rep* 40, 111171. 10.1016/j.celrep.2022.111171.
29. Ploenes, T., Pollok, A., Jockel, K.H., Kampe, S., Darwiche, K., Taube, C., Buer, J., and Aigner, C. (2022). The pathological oral cavity as a preventable source of postoperative pneumonia in thoracic surgery: a prospective observational study. *J Thorac Dis* 14, 822-831. 10.21037/jtd-21-1178.
30. Kirchhoff, L., Dittmer, S., Furnica, D.T., Buer, J., Steinmann, E., Rath, P.M., and Steinmann, J. (2022). Inhibition of azole-resistant *Aspergillus fumigatus* biofilm at various formation stages by antifungal drugs, including olorofim. *J Antimicrob Chemother* 77, 1645-1654. 10.1093/jac/dkaco62.
31. Kirchhoff, L., Braun, L., Schmidt, D., Dittmer, S., Dedy, J., Herbstreit, F., Stauff, R., Steckel, N.K., Buer, J., Rath, P.M., Steinmann, J., and Verhasselt, H.L. (2022). COVID-19-associated pulmonary aspergillosis in ICU patients in a German reference centre: phenotypic and molecular characterization of *Aspergillus fumigatus* isolates. *Mycoses*. 10.1111/myc.13430.
32. Hose, M., Gunther, A., Naser, E., Schumacher, F., Schonberger, T., Falkenstein, J., Papadamakis, A., Kleuser, B., Becker, K.A., Gulbins, E., Haimovitz-Friedman, A., Buer, J., Westendorf, A.M., and Hansen, W. (2022). Cell-intrinsic ceramides determine T cell function during melanoma progression. *Elife* 11. 10.7554/eLife.83073.
33. Gunther, A., Hose, M., Abberger, H., Schumacher, F., Veith, Y., Kleuser, B., Matuschewski, K., Lang, K.S., Gulbins, E., Buer, J., Westendorf, A., and Hansen, W. (2022). The acid

- ceramidase/ceramide axis controls parasitemia in *Plasmodium yoelii*-infected mice by regulating erythropoiesis. *Elife* 11. 10.7554/eLife.77975.
34. Bick, A., Buys, W., Engler, A., Madel, R., Atia, M., Faro, F., Westendorf, A.M., Limmer, A., Buer, J., Herbstreit, F., Kirschning, C.J., and Peters, J. (2022). Immune hyporeactivity to bacteria and multiple TLR-ligands, yet no response to checkpoint inhibition in patients just after meeting Sepsis-3 criteria. *PLoS One* 17, e0273247. 10.1371/journal.pone.0273247.
 35. Verhasselt, H.L., Buer, J., Dedy, J., Ziegler, R., Steinmann, J., Herbstreit, F., Brenner, T., and Rath, P.M. (2021). COVID-19 Co-infection with *Legionella pneumophila* in 2 Tertiary-Care Hospitals, Germany. *Emerg Infect Dis* 27, 1535-1537. 10.3201/eid2705.203388.
 36. Totzeck, A., Ramakrishnan, E., Schlag, M., Stolte, B., Kizina, K., Bolz, S., Thimm, A., Stettner, M., Marchesi, J.R., Buer, J., Kleinschnitz, C., Verhasselt, H.L., and Hagenacker, T. (2021). Gut bacterial microbiota in patients with myasthenia gravis: results from the MYBIOM study. *Ther Adv Neurol Dis* 14. ArtN 17562864211035657
10.1177/17562864211035657.
 37. Stähr, K.D., A.; Buer, J.; Lang, S. (2021). Meso- und Hypopharynx - Entzündungen. In Referenz HNO-Heilkunde O.K. Guntinas-Lichius, J.P.; Lang, S., ed. (Thieme), pp. 659-669.
 38. Scharmann, U., Kirchhoff, L., Hain, A., Buer, J., Koldehoff, M., Steinmann, J., and Rath, P.M. (2021). Evaluation of Three Commercial PCR Assays for the Detection of Azole-Resistant *Aspergillus fumigatus* from Respiratory Samples of Immunocompromised Patients. *J Fungi (Basel)* 7. 10.3390/jof7020132.
 39. Reinold, J., Farahpour, F., Fehring, C., Dolff, S., Konik, M., Korth, J., van Baal, L., Hoffmann, D., Buer, J., Witzke, O., Westendorf, A.M., and Kehrmann, J. (2021). A Pro-Inflammatory Gut Microbiome Characterizes SARS-CoV-2 Infected Patients and a Reduction in the Connectivity of an Anti-Inflammatory Bacterial Network Associates With Severe COVID-19. *Front Cell Infect Microbiol* 11, 747816. 10.3389/fcimb.2021.747816.
 40. Pastille, E., Fassnacht, T., Adamczyk, A., Ngo Thi Phuong, N., Buer, J., and Westendorf, A.M. (2021). Inhibition of TLR₄ Signaling Impedes Tumor Growth in Colitis-Associated Colon Cancer. *Front Immunol* 12, 669747. 10.3389/fimmu.2021.669747.
 41. Palmieri, V., Ebel, J.F., Ngo Thi Phuong, N., Klopffleisch, R., Vu, V.P., Adamczyk, A., Zoller, J., Riedel, C., Buer, J., Krebs, P., Hansen, W., Pastille, E., and Westendorf, A.M. (2021). Interleukin-33 signaling exacerbates experimental infectious colitis by enhancing gut permeability and inhibiting protective Th17 immunity. *Mucosal Immunol*. 10.1038/s41385-021-00386-7.
 42. Mahabadi, A.A., Mahmoud, I., Dykun, I., Totzeck, M., Rath, P.M., Ruhparwar, A., Buer, J., and Rassaf, T. (2021). Diagnostic value of the modified Duke criteria in suspected infective endocarditis -The PRO-ENDOCARDITIS study. *Int J Infect Dis* 104, 556-561. 10.1016/j.ijid.2021.01.046.
 43. Knuschke, T., Kollenda, S., Wenzek, C., Zelinsky, G., Steinbach, P., Dittmer, U., Buer, J., Eppe, M., and Westendorf, A.M. (2021). A Combination of Anti-PD-L1 Treatment and Therapeutic Vaccination Facilitates Improved Retroviral Clearance via Reactivation of Highly Exhausted T Cells. *mBio* 12. 10.1128/mBio.02121-20.
 44. Hansen, W., Luppus, S., Barthel, R., Chang, D.I., Broemstrup, J., Zwarg, T., Shibata, J., Westendorf, A.M., Buer, J., and Scherbaum, N. (2021). Heroin-assisted treatment of heroin-addicted patients normalizes regulatory T cells but does not restore CD4(+) T cell proliferation. *Addict Biol* 26, e12998. 10.1111/adb.12998.

45. Dröge, F.S., K.; Daser, A.; Buer, J.; Dominas, N. (2021). Mundhöhle - Infektionen. In Referenz HNO-Heilkunde O.K. Guntinas-Lichius, J.P.; Lang, S., ed. (Thieme), pp. 757-783.
46. Chapot, V., Effenberg, L., Dohmen-Ruetten, J., Buer, J., and Kehrmann, J. (2021). Evaluation of the Accelerate Pheno System for Rapid Identification and Antimicrobial Susceptibility Testing of Positive Blood Culture Bottles Inoculated with Primary Sterile Specimens from Patients with Suspected Severe Infections. *J Clin Microbiol* 59. 10.1128/JCM.02637-20.
47. Becker, K.A., Verhaegh, R., Verhasselt, H.L., Keitsch, S., Soddemann, M., Wilker, B., Wilson, G.C., Buer, J., Ahmad, S.A., Edwards, M.J., and Gulbins, E. (2021). Acid Ceramidase Rescues Cystic Fibrosis Mice from Pulmonary Infections. *Infect Immun* 89. 10.1128/IAI.00677-20.
48. Arweiler-Harbeck, D.B., J.; Saxe, J. (2021). Äußeres Ohr - Infektionen und Entzündungen. In Referenz HNO-Heilkunde O.K. Guntinas-Lichius, J.P.; Lang, S., ed. (Thieme), pp. 66-89.
49. Adamczyk, A., Pastille, E., Kehrmann, J., Vu, V.P., Geffers, R., Wasmer, M.H., Kasper, S., Schuler, M., Lange, C.M., Muggli, B., Rau, T.T., Klein, D., Hansen, W., Krebs, P., Buer, J., and Westendorf, A.M. (2021). GPR15 facilitates recruitment of regulatory T cells to promote colorectal cancer. *Cancer Res.* 10.1158/0008-5472.CAN-20-2133.
50. Abberger, H., Barthel, R., Bahr, J., Thiel, J., Lupp, S., Buer, J., Westendorf, A.M., and Hansen, W. (2021). Neuropilin-1 Is Expressed on Highly Activated CD4(+) Effector T Cells and Dysfunctional CD4(+) Conventional T Cells from Naive Mice. *J Immunol* 207, 1288-1297. 10.4049/jimmunol.2100222.
51. Zoller, J., Ebel, J.F., Khairnar, V., Schmitt, V., Klopffleisch, R., Meiners, J., Seiffart, V., Hansen, W., Buer, J., Singer, B.B., Lang, K.S., and Westendorf, A.M. (2020). CEACAM1 regulates CD8(+) T cell immunity and protects from severe pathology during *Citrobacter rodentium* induced colitis. *Gut Microbes*, 1-16. 10.1080/19490976.2020.1775464.
52. Westmeier, D., Siemer, S., Vallet, C., Steinmann, J., Docter, D., Buer, J., Knauer, S.K., and Stauber, R.H. (2020). Boosting nanotoxicity to combat multidrug-resistant bacteria in pathophysiological environments. *Nanoscale Adv* 2, 5428-5440. 10.1039/d0na00644k.
53. Scheffel, F., Knuschke, T., Otto, L., Kollenda, S., Sokolova, V., Cosmovici, C., Buer, J., Timm, J., Eppler, M., and Westendorf, A.M. (2020). Effective Activation of Human Antigen-Presenting Cells and Cytotoxic CD8(+) T Cells by a Calcium Phosphate-Based Nanoparticle Vaccine Delivery System. *Vaccines (Basel)* 8. 10.3390/vaccines8010110.
54. Scharmann, U., Verhasselt, H.L., Kirchhoff, L., Buer, J., Rath, P.M., Steinmann, J., and Ziegler, K. (2020). Evaluation of Two Lateral Flow Assays in BAL Fluids for the Detection of Invasive Pulmonary Aspergillosis: a Retrospective Two-Center Study. *Mycoses*. 10.1111/myc.13176.
55. Scharmann, U., Kirchhoff, L., Schmidt, D., Buer, J., Steinmann, J., and Rath, P.M. (2020). Evaluation of a Commercial Loop-mediated Isothermal Amplification (LAMP) Assay for Rapid Detection of *Pneumocystis jirovecii*. *Mycoses*. 10.1111/myc.13152.
56. Scharmann, U., Kirchhoff, L., Chapot, V.L.S., Dziobaka, J., Verhasselt, H.L., Stauff, R., Buer, J., Steinmann, J., and Rath, P.M. (2020). Comparison of four commercially available chromogenic media to identify *Candida albicans* and other medically relevant *Candida* species. *Mycoses*. 10.1111/myc.13119.
57. Pelzer, B.W., Seufert, R., Koldehoff, M., Liebrechts, T., Schmidt, D., Buer, J., Rath, P.M., and Steinmann, J. (2020). Performance of the AsperGenius(R) PCR assay for detecting azole resistant *Aspergillus fumigatus* in BAL fluids from allogeneic HSCT recipients: A prospective cohort study from Essen, West Germany. *Med Mycol* 58, 268-271. 10.1093/mmy/myz050.

58. Moelleken, M., Jockenhofer, F., Wiegand, C., Buer, J., Benson, S., and Dissemond, J. (2020). Pilot study on the influence of cold atmospheric plasma on bacterial contamination and healing tendency of chronic wounds. *J Dtsch Dermatol Ges.* 10.1111/ddg.14294.
59. Liedtke, K., Alter, C., Gunther, A., Hovelmeyer, N., Klopffleisch, R., Naumann, R., Wunderlich, F.T., Buer, J., Westendorf, A.M., and Hansen, W. (2020). Endogenous CD83 Expression in CD4(+) Conventional T Cells Controls Inflammatory Immune Responses. *J Immunol.* 10.4049/jimmunol.2000042.
60. Lang, S., Brandau, S., Marchesi, J.R., Jablonska, J., Thurnher, D., Mattheis, S., Buer, J., and Hussain, T. (2020). [The microbiome in head and neck tumors-initial findings and outlook]. *HNO.* 10.1007/s00106-020-00950-w.
61. Kirchhoff, L., Weisner, A.K., Schrepffer, M., Hain, A., Scharmann, U., Buer, J., Rath, P.M., and Steinmann, J. (2020). Phenotypical Characteristics of the Black Yeast *Exophiala dermatitidis* Are Affected by *Pseudomonas aeruginosa* in an Artificial Sputum Medium Mimicking Cystic Fibrosis-Like Conditions. *Front Microbiol* 11, 471. 10.3389/fmicb.2020.00471.
62. Kirchhoff, L., Dittmer, S., Weisner, A.K., Buer, J., Rath, P.M., and Steinmann, J. (2020). Antibiofilm activity of antifungal drugs, including the novel drug olorofim, against *Lomentospora prolificans*. *J Antimicrob Chemother.* 10.1093/jac/dkaa157.
63. Kirchhoff, L., Dittmer, S., Buer, J., Rath, P.M., and Steinmann, J. (2020). In vitro activity of olorofim (F901318) against fungi of the genus, *Scedosporium* and *Rasamsonia* as well as against *Lomentospora prolificans*, *Exophiala dermatitidis* and azole-resistant *Aspergillus fumigatus*. *Int J Antimicrob Agents*, 106105. 10.1016/j.ijantimicag.2020.106105.
64. Kirchhoff, L., Arweiler-Harbeck, D., Arnolds, J., Hussain, T., Hansen, S., Bertram, R., Buer, J., Lang, S., Steinmann, J., and Hoing, B. (2020). Imaging studies of bacterial biofilms on cochlear implants-Bioactive glass (BAG) inhibits mature biofilm. *PLoS One* 15, e0229198. 10.1371/journal.pone.0229198.
65. Kehrmann, J., Popp, W., Delgermaa, B., Otgonbayar, D., Gantumur, T., Buer, J., and Tsogbadrakh, N. (2020). Two fatal cases of plague after consumption of raw marmot organs. *Emerg Microbes Infect*, 1-6. 10.1080/22221751.2020.1807412.
66. Kehrmann, J., Effenberg, L., Wilk, C., Schoemer, D., Ngo Thi Phuong, N., Adamczyk, A., Pastille, E., Scholtysik, R., Klein-Hitpass, L., Klopffleisch, R., Westendorf, A.M., and Buer, J. (2020). Depletion of Foxp3(+) regulatory T cells is accompanied by an increase in the relative abundance of Firmicutes in the murine gut microbiome. *Immunology* 159, 344-353. 10.1111/imm.13158.
67. Hansen, W., Luppus, S., Barthel, R., Chang, D.I., Broemstrup, J., Zwarg, T., Shibata, J., Westendorf, A.M., Buer, J., and Scherbaum, N. (2020). Heroin-assisted treatment of heroin-addicted patients normalizes regulatory T cells but does not restore CD4(+) T cell proliferation. *Addict Biol*, e12998. 10.1111/adb.12998.
68. Domnich, M., Riedesel, J., Pylaeva, E., Kurten, C.H.L., Buer, J., Lang, S., and Jablonska, J. (2020). Oral Neutrophils: Underestimated Players in Oral Cancer. *Front Immunol* 11, 565683. 10.3389/fimmu.2020.565683.
69. Choudhury, A.R., Ju, Z.Y., Djojotubroto, M.W., Schienke, A., Lechel, A., Schaetzlein, S., Jiang, H., Stepczynska, A., Wang, C.F., Buer, J., Lee, H.W., von Zglinicki, T., Ganzer, A., Schirmacher, P., Nakauchi, H., and Rudolph, K.L. (2020). Cdkn1a deletion improves stem cell function and lifespan of mice with dysfunctional telomeres without accelerating cancer formation (vol 39, pg 99, 2007). *Nat Genet* 52, 548-548. 10.1038/s41588-020-0593-6.

70. Beck, S., Sehl, C., Voortmann, S., Verhasselt, H.L., Edwards, M.J., Buer, J., Hasenberg, M., Gulbins, E., and Becker, K.A. (2020). Sphingosine is able to prevent and eliminate *Staphylococcus epidermidis* biofilm formation on different orthopedic implant materials in vitro. *J Mol Med (Berl)* 98, 209-219. 10.1007/s00109-019-01858-x.
71. Verhasselt, H.L., Radke, J., Schmidt, D., Killengray, D., Scharmann, U., Rickerts, V., Hansen, W., Seidel, D., Falces-Romero, I., Buer, J., Rath, P.M., and Steinmann, J. (2019). Comparison of genotyping methods for *Cunninghamella bertholletiae*. *Mycoses*. 10.1111/myc.12908.
72. Thiel, J., Alter, C., Luppus, S., Eckstein, A., Tan, S., Fuhrer, D., Pastille, E., Westendorf, A.M., Buer, J., and Hansen, W. (2019). MicroRNA-183 and microRNA-96 are associated with autoimmune responses by regulating T cell activation. *J Autoimmun* 96, 94-103. 10.1016/j.jaut.2018.08.010.
73. Sokolova, V., Shi, Z., Huang, S., Du, Y., Kopp, M., Frede, A., Knuschke, T., Buer, J., Yang, D., Westendorf, A.M., and Eppler, M. (2019). Session 5: Biomaterials - Inorganic. *Biomed Tech (Berl)* 64, 36-40. 10.1515/bmt-2019-7005.
74. Ross, B., Krull, M., Rath, P., Kribben, A., Dopadlik, D., Erlemann, I., Wiegand-Szramek, I., Tyczynski, B., Buer, J., and Herbstreit, F. (2019). Dialysis drains as a possible source for carbapenem-resistant pathogens causing an ICU outbreak. *Infection* 47, 233-238. 10.1007/s15010-018-1239-9.
75. Pastille, E., Wasmer, M.H., Adamczyk, A., Vu, V.P., Mager, L.F., Phuong, N.N.T., Palmieri, V., Simillion, C., Hansen, W., Kasper, S., Schuler, M., Muggli, B., McCoy, K.D., Buer, J., Zlobec, I., Westendorf, A.M., and Krebs, P. (2019). The IL-33/ST2 pathway shapes the regulatory T cell phenotype to promote intestinal cancer. *Mucosal Immunol*. 10.1038/s41385-019-0176-y.
76. Ozmen, D., Ozkan, N., Guberina, N., Fliessbach, K., Suntharalingam, S., Theysohn, J., Buchter, M., Forsting, M., Buer, J., Dudda, M., Jager, M., and Wetter, A. (2019). Computed-tomography-guided biopsy in suspected spondylodiscitis: Single-center experience including 201 biopsy procedures. *Orthop Rev (Pavia)* 11, 7793. 10.4081/or.2019.7793.
77. Meiners, J., Palmieri, V., Klopffleisch, R., Ebel, J.F., Japtok, L., Schumacher, F., Yusuf, A.M., Becker, K.A., Zoller, J., Hose, M., Kleuser, B., Hermann, D.M., Kolesnick, R.N., Buer, J., Hansen, W., and Westendorf, A.M. (2019). Intestinal Acid Sphingomyelinase Protects From Severe Pathogen-Driven Colitis. *Front Immunol* 10, 1386. 10.3389/fimmu.2019.01386.
78. Krull, M., Steinmann, J., Heintschel von Heinegg, E., Buer, J., Sucharski, A., Mattheis, S., Lang, S., and Ross, B. (2019). Microbiological contamination of ear, nose and throat (ENT) units. *GMS Hyg Infect Control* 14, Doc03. 10.3205/dgkh000319.
79. Kieffer, D., Parohl, N., Buer, J., Ross, B., and Popp, W. (2019). Betten- und Nacttisch-Aufbereitung im Krankenhaus nach Entlassung - eine Pilotstudie. *HygMed* 44, D114-D117.
80. Kehrman, J., Menzel, J., Saeedghalati, M., Obeid, R., Schulze, C., Holzendorf, V., Farahpour, F., Reinsch, N., Klein-Hitpass, L., Streeck, H., Hoffmann, D., Buer, J., Esser, S., and Group, H.-H.S. (2019). Gut Microbiota in Human Immunodeficiency Virus-Infected Individuals Linked to Coronary Heart Disease. *J Infect Dis* 219, 497-508. 10.1093/infdis/jiy524.
81. Hesse, C., Kollenda, S., Rotan, O., Pastille, E., Adamczyk, A., Wenzek, C., Hansen, W., Eppler, M., Buer, J., Westendorf, A.M., and Knuschke, T. (2019). A Tumor-Peptide-Based Nanoparticle Vaccine Elicits Efficient Tumor Growth Control in Antitumor Immunotherapy. *Mol Cancer Ther* 18, 1069-1080. 10.1158/1535-7163.MCT-18-0764.
82. Bongard, J., Schmitz, A.L., Wolf, A., Zischinsky, G., Pieren, M., Schellhorn, B., Bravo-Rodriguez, K., Schillinger, J., Koch, U., Nussbaumer, P., Klebl, B., Steinmann, J., Buer, J., Sanchez-Garcia,

- E., Ehrmann, M., and Kaiser, M. (2019). Chemical validation of DegS as a target for the development of antibiotics with a novel mode of action. *ChemMedChem*. 10.1002/cmdc.201900193.
83. Beck, S., Sehl, C., Voortmann, S., Verhasselt, H.L., Edwards, M.J., Buer, J., Hasenberg, M., Gulbins, E., and Becker, K.A. (2019). Sphingosine is able to prevent and eliminate *Staphylococcus epidermidis* biofilm formation on different orthopedic implant materials in vitro. *J Mol Med*. 10.1007/s00109-019-01858-x.
84. Sokolova, V., Loza, K., Knuschke, T., Heinen-Weiler, J., Jastrow, H., Hasenberg, M., Buer, J., Westendorf, A.M., Gunzer, M., and Eppele, M. (2018). A systematic electron microscopic study on the uptake of barium sulphate nano-, submicro-, microparticles by bone marrow-derived phagocytosing cells. *Acta Biomater* 80, 352-363. 10.1016/j.actbio.2018.09.026.
85. Seufert, R., Sedlacek, L., Kahl, B., Hogardt, M., Hamprecht, A., Haase, G., Gunzer, F., Haas, A., Grauling-Halama, S., MacKenzie, C.R., Essig, A., Stehling, F., Sutharsan, S., Dittmer, S., Killengray, D., Schmidt, D., Eskandarian, N., Steinmann, E., Buer, J., Hagen, F., Meis, J.F., Rath, P.M., and Steinmann, J. (2018). Prevalence and characterization of azole-resistant *Aspergillus fumigatus* in patients with cystic fibrosis: a prospective multicentre study in Germany. *J Antimicrob Chemother* 73, 2047-2053. 10.1093/jac/dky147.
86. Robak, O.H., Heimesaat, M.M., Kruglov, A.A., Prepens, S., Ninnemann, J., Gutbier, B., Reppe, K., Hochrein, H., Suter, M., Kirschning, C.J., Marathe, V., Buer, J., Hornef, M.W., Schnare, M., Schneider, P., Witzernath, M., Bereswill, S., Steinhoff, U., Suttorp, N., Sander, L.E., Chaput, C., and Opitz, B. (2018). Antibiotic treatment-induced secondary IgA deficiency enhances susceptibility to *Pseudomonas aeruginosa* pneumonia. *J Clin Invest* 128, 3535-3545. 10.1172/JCI97065.
87. Olsowski, M., Hoffmann, F., Hain, A., Kirchhoff, L., Theegarten, D., Todt, D., Steinmann, E., Buer, J., Rath, P.M., and Steinmann, J. (2018). *Exophiala dermatitidis* isolates from various sources: using alternative invertebrate host organisms (*Caenorhabditis elegans* and *Galleria mellonella*) to determine virulence. *Sci Rep* 8, 12747. 10.1038/s41598-018-30909-5.
88. Knuschke, T., Rotan, O., Bayer, W., Kollenda, S., Dickow, J., Sutter, K., Hansen, W., Dittmer, U., Lang, K.S., Eppele, M., Buer, J., and Westendorf, A.M. (2018). Induction of Type I Interferons by Therapeutic Nanoparticle-Based Vaccination Is Indispensable to Reinforce Cytotoxic CD8(+) T Cell Responses During Chronic Retroviral Infection. *Front Immunol* 9, 614. 10.3389/fimmu.2018.00614.
89. Kehrman, J., Chapot, V., Buer, J., Rating, P., Bornfeld, N., and Steinmann, J. (2018). Diagnostic performance of blood culture bottles for vitreous culture compared to conventional microbiological cultures in patients with suspected endophthalmitis. *Eur J Clin Microbiol Infect Dis* 37, 889-895. 10.1007/s10096-017-3182-6.
90. Hoing, B., Kirchhoff, L., Arnolds, J., Hussain, T., Buer, J., Lang, S., Arweiler-Harbeck, D., and Steinmann, J. (2018). Bioactive Glass Granules Inhibit Mature Bacterial Biofilms on the Surfaces of Cochlear Implants. *Otol Neurotol* 39, e985-e991. 10.1097/MAO.0000000000002021.
91. Westendorf, A.M., Skibbe, K., Adamczyk, A., Buer, J., Geffers, R., Hansen, W., Pastille, E., and Jendrosseck, V. (2017). Hypoxia Enhances Immunosuppression by Inhibiting CD4+ Effector T Cell Function and Promoting Treg Activity. *Cell Physiol Biochem* 41, 1271-1284. 10.1159/000464429.
92. Ueffing, K., Abberger, H., Westendorf, A.M., Matuschewski, K., Buer, J., and Hansen, W. (2017). Conventional CD11c(high) Dendritic Cells Are Important for T Cell Priming during the Initial

- Phase of *Plasmodium yoelii* Infection, but Are Dispensable at Later Time Points. *Front Immunol* 8, 1333. 10.3389/fimmu.2017.01333.
93. Sokolova, V., Shi, Z., Huang, S., Du, Y., Kopp, M., Frede, A., Knuschke, T., Buer, J., Yang, D., Wu, J., Westendorf, A.M., and Eppler, M. (2017). Delivery of the TLR ligand poly(I:C) to liver cells in vitro and in vivo by calcium phosphate nanoparticles leads to a pronounced immunostimulation. *Acta Biomater* 64, 401-410. 10.1016/j.actbio.2017.09.037.
 94. Pastille, E., Frede, A., McSorley, H.J., Grab, J., Adamczyk, A., Kollenda, S., Hansen, W., Eppler, M., Buer, J., Maizels, R.M., Klopffleisch, R., and Westendorf, A.M. (2017). Intestinal helminth infection drives carcinogenesis in colitis-associated colon cancer. *PLoS Pathog* 13, e1006649. 10.1371/journal.ppat.1006649.
 95. Parohl, N., Stiefenhofer, D., Heiligtag, S., Reuter, H., Dopadlik, D., Mosel, F., Gerken, G., Dechene, A., Heintschel von Heinegg, E., Jochum, C., Buer, J., and Popp, W. (2017). Monitoring of endoscope reprocessing with an adenosine triphosphate (ATP) bioluminescence method. *GMS Hyg Infect Control* 12, Doc04. 10.3205/dgkh000289.
 96. Ma, Z., Liu, J., Wu, W., Zhang, E., Zhang, X., Li, Q., Zelinskyy, G., Buer, J., Dittmer, U., Kirschning, C.J., and Lu, M. (2017). The IL-1R/TLR signaling pathway is essential for efficient CD8(+) T-cell responses against hepatitis B virus in the hydrodynamic injection mouse model. *Cell Mol Immunol* 14, 997-1008. 10.1038/cmi.2017.43.
 97. Loevenich, K., Ueffing, K., Abel, S., Hose, M., Matuschewski, K., Westendorf, A.M., Buer, J., and Hansen, W. (2017). DC-Derived IL-10 Modulates Pro-inflammatory Cytokine Production and Promotes Induction of CD4(+)IL-10(+) Regulatory T Cells during *Plasmodium yoelii* Infection. *Front Immunol* 8, 152. 10.3389/fimmu.2017.00152.
 98. Klein, J.C., Moses, K., Zelinskyy, G., Sody, S., Buer, J., Lang, S., Helfrich, I., Dittmer, U., Kirschning, C.J., and Brandau, S. (2017). Combined toll-like receptor 3/7/9 deficiency on host cells results in T-cell-dependent control of tumour growth. *Nat Commun* 8, 14600. 10.1038/ncomms14600.
 99. Kirchhoff, L., Olsowski, M., Zilmans, K., Dittmer, S., Haase, G., Sedlacek, L., Steinmann, E., Buer, J., Rath, P.M., and Steinmann, J. (2017). Biofilm formation of the black yeast-like fungus *Exophiala dermatitidis* and its susceptibility to anti-infective agents. *Sci Rep* 7, 42886. 10.1038/srep42886.
 100. Kehrmann, J., Veckollari, B., Schmidt, D., Schildgen, O., Schildgen, V., Wagner, N., Zeschnigk, M., Klein-Hitpass, L., Witzke, O., Buer, J., and Steinmann, J. (2017). The lung microbiome in patients with pneumocystosis. *BMC Pulm Med* 17, 170. 10.1186/s12890-017-0512-5.
 101. Grosse-Onnebrink, J., Stehling, F., Tschiedel, E., Olivier, M., Mellies, U., Schmidt, R., Buer, J., Rath, P.M., and Steinmann, J. (2017). Bacteraemia and fungaemia in cystic fibrosis patients with febrile pulmonary exacerbation: a prospective observational study. *BMC Pulm Med* 17, 96. 10.1186/s12890-017-0440-4.
 102. Frede, A., Neuhaus, B., Knuschke, T., Wadwa, M., Kollenda, S., Klopffleisch, R., Hansen, W., Buer, J., Bruder, D., Eppler, M., and Westendorf, A.M. (2017). Local delivery of siRNA-loaded calcium phosphate nanoparticles abates pulmonary inflammation. *Nanomedicine* 13, 2395-2403. 10.1016/j.nano.2017.08.001.
 103. Adamczyk, A., Gageik, D., Frede, A., Pastille, E., Hansen, W., Rueffer, A., Buer, J., Buning, J., Langhorst, J., and Westendorf, A.M. (2017). Differential expression of GPR15 on T cells during ulcerative colitis. *JCI Insight* 2. 10.1172/jci.insight.90585.

104. Wadwa, M., Klopffleisch, R., Buer, J., and Westendorf, A.M. (2016). Targeting Antigens to Dec-205 on Dendritic Cells Induces Immune Protection in Experimental Colitis in Mice. *Eur J Microbiol Immunol (Bp)* 6, 1-8. 10.1556/1886.2015.00048.
105. Wadwa, M., Klopffleisch, R., Adamczyk, A., Frede, A., Pastille, E., Mahnke, K., Hansen, W., Geffers, R., Lang, K.S., Buer, J., Buning, J., and Westendorf, A.M. (2016). IL-10 downregulates CXCR3 expression on Th1 cells and interferes with their migration to intestinal inflammatory sites. *Mucosal Immunol* 9, 1263-1277. 10.1038/mi.2015.132.
106. Troger, B., Hartel, C., Buer, J., Dordelmann, M., Felderhoff-Muser, U., Hohn, T., Hepping, N., Hillebrand, G., Kribs, A., Marissen, J., Olbertz, D., Rath, P.M., Schmidtke, S., Siegel, J., Herting, E., Gopel, W., Steinmann, J., and Stein, A. (2016). Clinical Relevance of Pathogens Detected by Multiplex PCR in Blood of Very-Low-Birth Weight Infants with Suspected Sepsis - Multicentre Study of the German Neonatal Network. *PLoS One* 11, e0159821. 10.1371/journal.pone.0159821.
107. Steinmann, J., Dittmer, S., Houbraeken, J., Buer, J., and Rath, P.M. (2016). In Vitro Activity of Isavuconazole against *Rasamsonia* Species. *Antimicrob Agents Chemother* 60, 6890-6891. 10.1128/AAC.00742-16.
108. Steinmann, J., Buer, J., and Rath, P.M. (2016). Detection of *Aspergillus fumigatus* in Blood Samples from Critically Ill Patients in Intensive Care Units by Use of the SeptiFast Assay. *J Clin Microbiol* 54, 1918-1921. 10.1128/JCM.00478-16.
109. Krull, M., Klare, I., Ross, B., Trenchel, R., Beelen, D.W., Todt, D., Steinmann, E., Buer, J., Rath, P.M., and Steinmann, J. (2016). Emergence of linezolid- and vancomycin-resistant *Enterococcus faecium* in a department for hematologic stem cell transplantation. *Antimicrob Resist Infect Control* 5, 31. 10.1186/s13756-016-0131-6.
110. Knuschke, T., Rotan, O., Bayer, W., Sokolova, V., Hansen, W., Sparwasser, T., Dittmer, U., Epple, M., Buer, J., and Westendorf, A.M. (2016). Combination of nanoparticle-based therapeutic vaccination and transient ablation of regulatory T cells enhances anti-viral immunity during chronic retroviral infection. *Retrovirology* 13, 24. 10.1186/s12977-016-0258-9.
111. Klotz, U., Schmidt, D., Willinger, B., Steinmann, E., Buer, J., Rath, P.M., and Steinmann, J. (2016). Echinocandin resistance and population structure of invasive *Candida glabrata* isolates from two university hospitals in Germany and Austria. *Mycoses* 59, 312-318. 10.1111/myc.12472.
112. Kehrmann, J., Wessel, S., Murali, R., Hampel, A., Bange, F.C., Buer, J., and Mosel, F. (2016). Principal component analysis of MALDI TOF MS mass spectra separates *M. abscessus* (sensu stricto) from *M. massiliense* isolates. *BMC Microbiol* 16, 24. 10.1186/s12866-016-0636-4.
113. Kehrmann, J., Schoerding, A.K., Murali, R., Wessel, S., Koehling, H.L., Mosel, F., and Buer, J. (2016). Performance of Vitek MS in identifying nontuberculous mycobacteria from MGIT liquid medium and Lowenstein-Jensen solid medium. *Diagn Microbiol Infect Dis* 84, 43-47. 10.1016/j.diagmicrobio.2015.10.007.
114. Kehrmann, J., Kurt, N., Rueger, K., Bange, F.C., and Buer, J. (2016). GenoType NTM-DR for Identifying *Mycobacterium abscessus* Subspecies and Determining Molecular Resistance. *J Clin Microbiol* 54, 1653-1655. 10.1128/JCM.00147-16.
115. Gollnick, H.P., Buer, J., Beissert, S., and Sunderkatter, C. (2016). Verantwortlicher Umgang mit Antibiotika: Notwendigkeit der Antibiotikareduktion in der Aknetherapie. *J Dtsch Dermatol Ges* 14, 1319-1327. 10.1111/ddg.13048.

116. Gamrad, L., Rehbock, C., Westendorf, A.M., Buer, J., Barcikowski, S., and Hansen, W. (2016). Efficient nucleic acid delivery to murine regulatory T cells by gold nanoparticle conjugates. *Sci Rep* 6, 28709. 10.1038/srep28709.
117. Frede, A., Neuhaus, B., Klopffleisch, R., Walker, C., Buer, J., Muller, W., Epple, M., and Westendorf, A.M. (2016). Colonic gene silencing using siRNA-loaded calcium phosphate/PLGA nanoparticles ameliorates intestinal inflammation in vivo. *J Control Release* 222, 86-96. 10.1016/j.jconrel.2015.12.021.
118. Abel, S., Ueffing, K., Tatura, R., Hutzler, M., Hose, M., Matuschewski, K., Kehrmann, J., Westendorf, A.M., Buer, J., and Hansen, W. (2016). *Plasmodium yoelii* infection of BALB/c mice results in expansion rather than induction of CD4(+) Foxp3(+) regulatory T cells. *Immunology* 148, 197-205. 10.1111/imm.12602.
119. Tatura, R., Zeschnigk, M., Hansen, W., Steinmann, J., Vidigal, P.G., Hutzler, M., Pastille, E., Westendorf, A.M., Buer, J., and Kehrmann, J. (2015). Relevance of Foxp3(+) regulatory T cells for early and late phases of murine sepsis. *Immunology* 146, 144-156. 10.1111/imm.12490.
120. Steinmann, J., Hamprecht, A., Vehreschild, M.J., Cornely, O.A., Buchheidt, D., Spiess, B., Koldehoff, M., Buer, J., Meis, J.F., and Rath, P.M. (2015). Emergence of azole-resistant invasive aspergillosis in HSCT recipients in Germany. *J Antimicrob Chemother* 70, 1522-1526. 10.1093/jac/dku566.
121. Seiffart, V., Zoeller, J., Klopffleisch, R., Wadwa, M., Hansen, W., Buer, J., Riedel, C., and Westendorf, A.M. (2015). IL10-Deficiency in CD4(+) T Cells Exacerbates the IFNgamma and IL17 Response During Bacteria Induced Colitis. *Cell Physiol Biochem* 36, 1259-1273. 10.1159/000430295.
122. Rath, P.M., Schoch, B., Adamzik, M., Steinmann, E., Buer, J., and Steinmann, J. (2015). Reply: PCR assay for pathogen detection in ventriculostomy-related meningitis in neurosurgery patients: unanswered questions? *Infection* 43, 251-252. 10.1007/s15010-015-0725-6.
123. Niezold, T., Storcksdieck Genannt Bonsmann, M., Maaske, A., Temchura, V., Heinecke, V., Hannaman, D., Buer, J., Ehrhardt, C., Hansen, W., Uberla, K., and Tenbusch, M. (2015). DNA vaccines encoding DEC205-targeted antigens: immunity or tolerance? *Immunology* 145, 519-533. 10.1111/imm.12467.
124. Kruger, A., Oldenburg, M., Chebrolu, C., Beisser, D., Kolter, J., Sigmund, A.M., Steinmann, J., Schafer, S., Hochrein, H., Rahmann, S., Wagner, H., Henneke, P., Hornung, V., Buer, J., and Kirschning, C.J. (2015). Human TLR8 senses UR/URR motifs in bacterial and mitochondrial RNA. *EMBO Rep* 16, 1656-1663. 10.15252/embr.201540861.
125. Koehling, H.L., Willinger, B., Buer, J., Rath, P.M., and Steinmann, J. (2015). Comparative evaluation of a new commercial colorimetric microdilution assay (SensiQuattro Candida EU) with MIC test strip and EUCAST broth microdilution methods for susceptibility testing of invasive *Candida* isolates. *J Clin Microbiol* 53, 255-261. 10.1128/JCM.02830-14.
126. Chebrolu, C., Artner, D., Sigmund, A.M., Buer, J., Zamyatina, A., and Kirschning, C.J. (2015). Species and mediator specific TLR4 antagonism in primary human and murine immune cells by betaGlcN(1<-->1)alphaGlc based lipid A mimetics. *Mol Immunol* 67, 636-641. 10.1016/j.molimm.2015.07.037.
127. Vidigal, P.G., Musken, M., Becker, K.A., Haussler, S., Wingender, J., Steinmann, E., Kehrmann, J., Gulbins, E., Buer, J., Rath, P.M., and Steinmann, J. (2014). Effects of green tea compound epigallocatechin-3-gallate against *Stenotrophomonas maltophilia* infection and biofilm. *PLoS One* 9, e92876. 10.1371/journal.pone.0092876.

128. Vidigal, P.G., Mosel, F., Koehling, H.L., Mueller, K.D., Buer, J., Rath, P.M., and Steinmann, J. (2014). Delineation of *Stenotrophomonas maltophilia* isolates from cystic fibrosis patients by fatty acid methyl ester profiles and matrix-assisted laser desorption/ionization time-of-flight mass spectra using hierarchical cluster analysis and principal component analysis. *J Med Microbiol* 63, 1615-1620. 10.1099/jmm.0.076950-0.
129. Vidigal, P.G., Dittmer, S., Steinmann, E., Buer, J., Rath, P.M., and Steinmann, J. (2014). Adaptation of *Stenotrophomonas maltophilia* in cystic fibrosis: molecular diversity, mutation frequency and antibiotic resistance. *Int J Med Microbiol* 304, 613-619. 10.1016/j.ijmm.2014.04.002.
130. Steinmann, J., Giraud, S., Schmidt, D., Sedlacek, L., Hamprecht, A., Houbraken, J., Meis, J.F., Bouchara, J.P., Buer, J., and Rath, P.M. (2014). Validation of a novel real-time PCR for detecting *Rasamsonia argillacea* species complex in respiratory secretions from cystic fibrosis patients. *New Microbes New Infect* 2, 72-78. 10.1002/nmi2.44.
131. Ross, B., Steinmann, J., Buer, J., Dusse, F., Jakob, H., Schneemann, H., Hugo-Hanke, S., Brautigam, S., Sanewski, A., Kundt, R., Parohl, N., Weidler, K., Witzke, O., and Popp, W. (2014). [Outbreak with *Ralstonia pickettii* caused by contaminated magnesium vials]. *Dtsch Med Wochenschr* 139, 323-326. 10.1055/s-0033-1360059.
132. Rath, P.M., Schoch, B., Adamzik, M., Steinmann, E., Buer, J., and Steinmann, J. (2014). Value of multiplex PCR using cerebrospinal fluid for the diagnosis of ventriculostomy-related meningitis in neurosurgery patients. *Infection* 42, 621-627. 10.1007/s15010-014-0590-8.
133. Pastille, E., Bardini, K., Fleissner, D., Adamczyk, A., Frede, A., Wadwa, M., von Smolinski, D., Kasper, S., Sparwasser, T., Gruber, A.D., Schuler, M., Sakaguchi, S., Roers, A., Muller, W., Hansen, W., Buer, J., and Westendorf, A.M. (2014). Transient ablation of regulatory T cells improves antitumor immunity in colitis-associated colon cancer. *Cancer Res* 74, 4258-4269. 10.1158/0008-5472.CAN-13-3065.
134. Langhorst, J., Frede, A., Knott, M., Pastille, E., Buer, J., Dobos, G.J., and Westendorf, A.M. (2014). Distinct kinetics in the frequency of peripheral CD4+ T cells in patients with ulcerative colitis experiencing a flare during treatment with mesalazine or with a herbal preparation of myrrh, chamomile, and coffee charcoal. *PLoS One* 9, e104257. 10.1371/journal.pone.0104257.
135. Kozlova, D., Sokolova, V., Zhong, M., Zhang, E., Yang, J., Li, W., Yang, Y., Buer, J., Westendorf, A.M., Eppler, M., and Yan, H. (2014). Calcium phosphate nanoparticles show an effective activation of the innate immune response in vitro and in vivo after functionalization with flagellin. *Virol Sin* 29, 33-39. 10.1007/s12250-014-3379-0.
136. Knuschke, T., Bayer, W., Rotan, O., Sokolova, V., Wadwa, M., Kirschning, C.J., Hansen, W., Dittmer, U., Eppler, M., Buer, J., and Westendorf, A.M. (2014). Prophylactic and therapeutic vaccination with a nanoparticle-based peptide vaccine induces efficient protective immunity during acute and chronic retroviral infection. *Nanomedicine* 10, 1787-1798. 10.1016/j.nano.2014.06.014.
137. Kehrmann, J., Tatura, R., Zeschnigk, M., Probst-Kepper, M., Geffers, R., Steinmann, J., and Buer, J. (2014). Impact of 5-aza-2'-deoxycytidine and epigallocatechin-3-gallate for induction of human regulatory T cells. *Immunology* 142, 384-395. 10.1111/imm.12261.
138. Jost, N.H., Abel, S., Hutzler, M., Sparwasser, T., Zimmermann, A., Roers, A., Muller, W., Klopffleisch, R., Hengel, H., Westendorf, A.M., Buer, J., and Hansen, W. (2014). Regulatory T cells and T-cell-derived IL-10 interfere with effective anti-cytomegalovirus immune response. *Immunol Cell Biol* 92, 860-871. 10.1038/icb.2014.62.

139. Jockenhofer, F., Chapot, V., Stoffels-Weindorf, M., Korber, A., Klode, J., Buer, J., Kupper, B., Roesch, A., and Dissemond, J. (2014). Bacterial spectrum colonizing chronic leg ulcers: a 10-year comparison from a German wound care center. *J Dtsch Dermatol Ges* 12, 1121-1127. 10.1111/ddg.12540.
140. Herz, J., Hagen, S.I., Bergmuller, E., Sabellek, P., Gothert, J.R., Buer, J., Hansen, W., Hermann, D.M., and Doeppner, T.R. (2014). Exacerbation of ischemic brain injury in hypercholesterolemic mice is associated with pronounced changes in peripheral and cerebral immune responses. *Neurobiol Dis* 62, 456-468. 10.1016/j.nbd.2013.10.022.
141. Al Ghazal, P., Korber, A., Klode, J., Schmid, E.N., Buer, J., and Dissemond, J. (2014). Evaluation of the Essen Rotary as a new technique for bacterial swabs: results of a prospective controlled clinical investigation in 50 patients with chronic leg ulcers. *Int Wound J* 11, 44-49. 10.1111/j.1742-481X.2012.01036.x.
142. Steinmann, J., Buer, J., Pietschmann, T., and Steinmann, E. (2013). Anti-infective properties of epigallocatechin-3-gallate (EGCG), a component of green tea. *Br J Pharmacol* 168, 1059-1073. 10.1111/bph.12009.
143. Sokolova, V., Kozlova, D., Knuschke, T., Buer, J., Westendorf, A.M., and Eppler, M. (2013). Mechanism of the uptake of cationic and anionic calcium phosphate nanoparticles by cells. *Acta Biomater* 9, 7527-7535. 10.1016/j.actbio.2013.02.034.
144. Schemuth, H., Dittmer, S., Lackner, M., Sedlacek, L., Hamprecht, A., Steinmann, E., Buer, J., Rath, P.M., and Steinmann, J. (2013). In vitro activity of colistin as single agent and in combination with antifungals against filamentous fungi occurring in patients with cystic fibrosis. *Mycoses* 56, 297-303. 10.1111/myc.12022.
145. Knuschke, T., Sokolova, V., Rotan, O., Wadwa, M., Tenbusch, M., Hansen, W., Staeheli, P., Eppler, M., Buer, J., and Westendorf, A.M. (2013). Immunization with biodegradable nanoparticles efficiently induces cellular immunity and protects against influenza virus infection. *J Immunol* 190, 6221-6229. 10.4049/jimmunol.1202654.
146. Goncalves Vidigal, P., Schmidt, D., Stehling, F., Mellies, U., Steinmann, E., Buer, J., Rath, P.M., and Steinmann, J. (2013). Development of a quantitative immunofluorescence assay for detection of *Stenotrophomonas maltophilia* antibodies in patients with cystic fibrosis. *J Cyst Fibros* 12, 651-654. 10.1016/j.jcf.2013.04.011.
147. Tschiedel, E., Steinmann, J., Buer, J., Onnebrink, J.G., Felderhoff-Muser, U., Rath, P.M., and Dohna-Schwake, C. (2012). Results and relevance of molecular detection of pathogens by SeptiFast--a retrospective analysis in 75 critically ill children. *Klin Padiatr* 224, 12-16. 10.1055/s-0031-1285878.
148. Tosiek, M.J., Bader, S.R., Gruber, A.D., Buer, J., Gereke, M., and Bruder, D. (2012). CD8(+) T cells responding to alveolar self-antigen lack CD25 expression and fail to precipitate autoimmunity. *Am J Respir Cell Mol Biol* 47, 869-878. 10.1165/rcmb.2011-0387OC.
149. Tatura, R., Zeschnigk, M., Adamzik, M., Probst-Kepper, M., Buer, J., and Kehrmann, J. (2012). Quantification of regulatory T cells in septic patients by real-time PCR-based methylation assay and flow cytometry. *PLoS One* 7, e49962. 10.1371/journal.pone.0049962.
150. Ross, B., Witzke, O., Kribben, A., Heintschel von Heinegg, E., Buer, J., Gerken, G., Fiedler, M., and Popp, W. (2012). [Managing EHEC in hospital routine]. *Dtsch Med Wochenschr* 137, 933-936. 10.1055/s-0032-1304923.
151. Riss, G.L., Chang, D.I., Wevers, C., Westendorf, A.M., Buer, J., Scherbaum, N., and Hansen, W. (2012). Opioid maintenance therapy restores CD4+ T cell function by normalizing

- CD4+CD25(high) regulatory T cell frequencies in heroin user. *Brain Behav Immun* 26, 972-978. 10.1016/j.bbi.2012.05.008.
152. Rath, P.M., Saner, F., Paul, A., Lehmann, N., Steinmann, E., Buer, J., and Steinmann, J. (2012). Multiplex PCR for rapid and improved diagnosis of bloodstream infections in liver transplant recipients. *J Clin Microbiol* 50, 2069-2071. 10.1128/JCM.00745-12.
 153. Rath, P.M., Buchheidt, D., Spiess, B., Arfanis, E., Buer, J., and Steinmann, J. (2012). First reported case of azole-resistant *aspergillus fumigatus* due to the TR/L98H mutation in Germany. *Antimicrob Agents Chemother* 56, 6060-6061. 10.1128/AAC.01017-12.
 154. Oldenburg, M., Kruger, A., Ferstl, R., Kaufmann, A., Nees, G., Sigmund, A., Bathke, B., Lauterbach, H., Suter, M., Dreher, S., Koedel, U., Akira, S., Kawai, T., Buer, J., Wagner, H., Bauer, S., Hochrein, H., and Kirschning, C.J. (2012). TLR13 recognizes bacterial 23S rRNA devoid of erythromycin resistance-forming modification. *Science* 337, 1111-1115. 10.1126/science.1220363.
 155. Metz, C.H., Buer, J., Bornfeld, N., and Lipski, A. (2012). Bilateral *Bartonella henselae* neuroretinitis with stellate maculopathy in a 6-year-old boy. *Infection* 40, 191-194. 10.1007/s15010-011-0168-7.
 156. Kozlova, D., Chernousova, S., Knuschke, T., Buer, J., Westendorf, A.M., and Epple, M. (2012). Cell targeting by antibody-functionalized calcium phosphate nanoparticles. *J Mater Chem* 22, 396-404. 10.1039/c1jm14683a.
 157. Kohling, H.L., Bittner, A., Muller, K.D., Buer, J., Becker, M., Rubben, H., Rettenmeier, A.W., and Mosel, F. (2012). Direct identification of bacteria in urine samples by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and relevance of defensins as interfering factors. *J Med Microbiol* 61, 339-344. 10.1099/jmm.0.032284-0.
 158. Jeron, A., Hansen, W., Ewert, F., Buer, J., Geffers, R., and Bruder, D. (2012). ChIP-on-chip analysis identifies IL-22 as direct target gene of ectopically expressed FOXP3 transcription factor in human T cells. *BMC Genomics* 13, 705. 10.1186/1471-2164-13-705.
 159. Heintschel von Heinegg, E., Steinmann, J., Buer, J., and Rath, P. (2012). Infektionen durch Pilze. In *Labor und Diagnose*, L. Thomas, ed. (TH-Books), pp. 2127-2143.
 160. Hansen, W., Hutzler, M., Abel, S., Alter, C., Stockmann, C., Kliche, S., Albert, J., Sparwasser, T., Sakaguchi, S., Westendorf, A.M., Schadendorf, D., Buer, J., and Helfrich, I. (2012). Neuropilin 1 deficiency on CD4+Foxp3+ regulatory T cells impairs mouse melanoma growth. *J Exp Med* 209, 2001-2016. 10.1084/jem.20111497.
 161. Abel, S., Luckheide, N., Westendorf, A.M., Geffers, R., Roers, A., Muller, W., Sparwasser, T., Matuschewski, K., Buer, J., and Hansen, W. (2012). Strong impact of CD4+ Foxp3+ regulatory T cells and limited effect of T cell-derived IL-10 on pathogen clearance during *Plasmodium yoelii* infection. *J Immunol* 188, 5467-5477. 10.4049/jimmunol.1102223.
 162. Tosiek, M.J., Gruber, A.D., Bader, S.R., Mavel, S., Hoymann, H.G., Prettin, S., Tschernig, T., Buer, J., Gereke, M., and Bruder, D. (2011). CD4+CD25+Foxp3+ regulatory T cells are dispensable for controlling CD8+ T cell-mediated lung inflammation. *J Immunol* 186, 6106-6118. 10.4049/jimmunol.1000632.
 163. Steinmann, J., Schmidt, D., Buer, J., and Rath, P.M. (2011). Discrimination of *Scedosporium prolificans* against *Pseudallescheria boydii* and *Scedosporium apiospermum* by semiautomated repetitive sequence-based PCR. *Med Mycol* 49, 475-483. 10.3109/13693786.2010.539630.
 164. Steinmann, J., Kaase, M., Gatermann, S., Popp, W., Steinmann, E., Damman, M., Paul, A., Saner, F., Buer, J., and Rath, P. (2011). Outbreak due to a *Klebsiella pneumoniae* strain

- harbouring KPC-2 and VIM-1 in a German university hospital, July 2010 to January 2011. *Euro Surveill* 16.
165. Steinmann, J., Huelsewede, J., Buer, J., and Rath, P.M. (2011). Comparison and evaluation of a novel bioassay and high-performance liquid chromatography for the clinical measurement of serum voriconazole concentrations. *Mycoses* 54, e421-428. 10.1111/j.1439-0507.2010.01938.x.
 166. Sokolova, V., Knuschke, T., Buer, J., Westendorf, A.M., and Eppler, M. (2011). Quantitative determination of the composition of multi-shell calcium phosphate-oligonucleotide nanoparticles and their application for the activation of dendritic cells. *Acta Biomater* 7, 4029-4036. 10.1016/j.actbio.2011.07.010.
 167. Schenk, U., Frascoli, M., Proietti, M., Geffers, R., Traggiai, E., Buer, J., Ricordi, C., Westendorf, A.M., and Grassi, F. (2011). ATP inhibits the generation and function of regulatory T cells through the activation of purinergic P2X receptors. *Sci Signal* 4, ra12. 10.1126/scisignal.2001270.
 168. Lipski, A., Buer, J., Bornfeld, N., and Metz, C. (2011). Katzenkrankheit - ein dicker Floh im Heuhaufen? . *Z. prakt. Augenheilkd.* 32, 409-412.
 169. Kehrmann, J., Zeschneigk, M., Buer, J., and Probst-Kepper, M. (2011). FOXP3 Expression in GARP-Transduced Helper T Cells Is Not Associated with FOXP3 TSDR Demethylation. *Transfus Med Hemother* 38, 287-291. 000331499.
 170. Goncalves-Vidigal, P., Grosse-Onnebrink, J., Mellies, U., Buer, J., Rath, P.M., and Steinmann, J. (2011). *Stenotrophomonas maltophilia* in cystic fibrosis: improved detection by the use of selective agar and evaluation of antimicrobial resistance. *J Cyst Fibros* 10, 422-427. 10.1016/j.jcf.2011.06.010.
 171. Fleissner, D., Loser, K., Hansen, W., Dissemond, J., Korber, A., Beissert, S., Buer, J., and Westendorf, A.M. (2011). In vitro induced CD8+ regulatory T cells inhibit skin inflammation. *Eur J Microbiol Immunol (Bp)* 1, 208-214. 10.1556/EuJMI.1.2011.3.4.
 172. Fleissner, D., Frede, A., Knott, M., Knuschke, T., Geffers, R., Hansen, W., Dobos, G., Langhorst, J., Buer, J., and Westendorf, A.M. (2011). Generation and function of immunosuppressive human and murine CD8+ T cells by transforming growth factor-beta and retinoic acid. *Immunology* 134, 82-92. 10.1111/j.1365-2567.2011.03469.x.
 173. Westendorf, A.M., Fleissner, D., Hansen, W., and Buer, J. (2010). T cells, dendritic cells and epithelial cells in intestinal homeostasis. *Int J Med Microbiol* 300, 11-18. 10.1016/j.ijmm.2009.08.009.
 174. Vernadakis, S., Adamzik, M., Heuer, M., Antoch, G., Baba, H., Fiedler, M., Buer, J., Paul, A., and Kaiser, G.M. (2010). [Hemicolectomy for ischemic colitis : A case report of a (H1N1) virus-associated death]. *Chirurg* 81, 841-845. 10.1007/s00104-010-1894-6.
 175. Trunk, K., Benkert, B., Quack, N., Munch, R., Scheer, M., Garbe, J., Jansch, L., Trost, M., Wehland, J., Buer, J., Jahn, M., Schobert, M., and Jahn, D. (2010). Anaerobic adaptation in *Pseudomonas aeruginosa*: definition of the Anr and Dnr regulons. *Environ Microbiol* 12, 1719-1733. 10.1111/j.1462-2920.2010.02252.x.
 176. Steinmann, J., Buer, J., and Rath, P.M. (2010). Caspofungin: cross-reactivity in the *Aspergillus* antigen assay. *J Clin Microbiol* 48, 2313. 10.1128/JCM.00118-10.
 177. Sokolova, V., Knuschke, T., Kovtun, A., Buer, J., Eppler, M., and Westendorf, A.M. (2010). The use of calcium phosphate nanoparticles encapsulating Toll-like receptor ligands and the antigen hemagglutinin to induce dendritic cell maturation and T cell activation. *Biomaterials* 31, 5627-5633. 10.1016/j.biomaterials.2010.03.067.

178. Probst-Kepper, M., and Buer, J. (2010). FOXP3 and GARP (LRRC32): the master and its minion. *Biol Direct* 5, 8. 10.1186/1745-6150-5-8.
179. Probst-Kepper, M., Balling, R., and Buer, J. (2010). FOXP3: required but not sufficient. the role of GARP (LRRC32) as a safeguard of the regulatory phenotype. *Curr Mol Med* 10, 533-539.
180. Popp, W., Buer, J., Rath, P.-M., Steinmann, J., Kundt, R., Scheytt, C., and Hansen, D. (2010). MRSA - aktuelle Entwicklungen, drängende Probleme. *Krh.-Hyg. + Inf.verh.* 32, 144-150.
181. Menning, A., Loddenkemper, C., Westendorf, A.M., Szilagyi, B., Buer, J., Siewert, C., Hamann, A., and Huehn, J. (2010). Retinoic acid-induced gut tropism improves the protective capacity of Treg in acute but not in chronic gut inflammation. *Eur J Immunol* 40, 2539-2548. 10.1002/eji.200939938.
182. Korber, A., Schmid, E.N., Buer, J., Klode, J., Schadendorf, D., and Dissemmond, J. (2010). Bacterial colonization of chronic leg ulcers: current results compared with data 5 years ago in a specialized dermatology department. *J Eur Acad Dermatol Venereol* 24, 1017-1025. 10.1111/j.1468-3083.2010.03570.x.
183. Hansen, W., Westendorf, A.M., Toepfer, T., Mauel, S., Geffers, R., Gruber, A.D., and Buer, J. (2010). Inflammation in vivo is modulated by GPR83 isoform-4 but not GPR83 isoform-1 expression in regulatory T cells. *Genes Immun* 11, 357-361. 10.1038/gene.2010.5.
184. Fleissner, D., Hansen, W., Geffers, R., Buer, J., and Westendorf, A.M. (2010). Local induction of immunosuppressive CD8+ T cells in the gut-associated lymphoid tissues. *PLoS One* 5, e15373. 10.1371/journal.pone.0015373.
185. Bar-On, L., Birnberg, T., Lewis, K.L., Edelson, B.T., Bruder, D., Hildner, K., Buer, J., Murphy, K.M., Reizis, B., and Jung, S. (2010). CX3CR1+ CD8alpha+ dendritic cells are a steady-state population related to plasmacytoid dendritic cells. *Proc Natl Acad Sci U S A* 107, 14745-14750. 10.1073/pnas.1001562107.
186. Westendorf, A.M., Fleissner, D., Groebe, L., Jung, S., Gruber, A.D., Hansen, W., and Buer, J. (2009). CD4+Foxp3+ regulatory T cell expansion induced by antigen-driven interaction with intestinal epithelial cells independent of local dendritic cells. *Gut* 58, 211-219. 10.1136/gut.2008.151720.
187. Walter, U.B., J. (2009). Single cell immunology. In *Single cell analysis - Technologies and applications*, D. Anselmetti, ed. (Wiley-VCH), pp. 175-196.
188. Ukena, S.N., Koenecke, C., Geffers, R., Fuehner, T., Welte, T., Ganser, A., Buer, J., and Franzke, A. (2009). T helper type 2 differentiation is associated with induction of antibacterial defense mechanisms in blood lymphocytes of patients with sarcoidosis. *Immunol Invest* 38, 49-66. 10.1080/08820130802572103.
189. TrehanPati, N., Geffers, R., Sukriti, Hissar, S., Riese, P., Toepfer, T., Buer, J., Kumar, M., Guzman, C.A., and Sarin, S.K. (2009). Gene expression signatures of peripheral CD4+ T cells clearly discriminate between patients with acute and chronic hepatitis B infection. *Hepatology* 49, 781-790. 10.1002/hep.22696.
190. Steinmann, J., Marggraf, G., Buer, J., and Rath, P.M. (2009). Syphilis-specific immunoglobulin G seroconversion after double-lung transplantation. *J Heart Lung Transplant* 28, 857-859. 10.1016/j.healun.2009.04.029.
191. Steinmann, J., Buer, J., Rath, P.M., Paul, A., and Saner, F. (2009). Invasive aspergillosis in two liver transplant recipients: diagnosis by SeptiFast. *Transpl Infect Dis* 11, 175-178. 10.1111/j.1399-3062.2009.00367.x.

192. Stark, L., Matussek, A., Strindhall, J., Geffers, R., Buer, J., Kihlstrom, E., Monnecke, S., Lofgren, S., and Lindgren, P.E. (2009). Staphylococcus aureus isolates from blood and anterior nares induce similar innate immune responses in endothelial cells. *APMIS* 117, 814-824. 10.1111/j.1600-0463.2009.02535.x.
193. Probst-Kepper, M., Kroger, A., Garritsen, H.S., and Buer, J. (2009). Perspectives on Regulatory T Cell Therapies. *Transfus Med Hemother* 36, 302-308. 10.1159/000235929.
194. Probst-Kepper, M., Geffers, R., Kroger, A., Viegas, N., Erck, C., Hecht, H.J., Lunsdorf, H., Roubin, R., Moharreggh-Khiabani, D., Wagner, K., Ocklenburg, F., Jeron, A., Garritsen, H., Arstila, T.P., Kekalainen, E., Balling, R., Hauser, H., Buer, J., and Weiss, S. (2009). GARP: a key receptor controlling FOXP3 in human regulatory T cells. *J Cell Mol Med* 13, 3343-3357. 10.1111/j.1582-4934.2009.00782.x.
195. Lahl, K., Mayer, C.T., Bopp, T., Huehn, J., Loddenkemper, C., Eberl, G., Wirnsberger, G., Dornmair, K., Geffers, R., Schmitt, E., Buer, J., and Sparwasser, T. (2009). Nonfunctional regulatory T cells and defective control of Th2 cytokine production in natural scurfy mutant mice. *J Immunol* 183, 5662-5672. 10.4049/jimmunol.0803762.
196. Jeron, A., Pfoertner, S., Bruder, D., Geffers, R., Hammerer, P., Hofmann, R., Buer, J., and Schrader, A.J. (2009). Frequency and gene expression profile of regulatory T cells in renal cell carcinoma. *Tumour Biol* 30, 160-170. 10.1159/000228909.
197. Gereke, M., Jung, S., Buer, J., and Bruder, D. (2009). Alveolar type II epithelial cells present antigen to CD4(+) T cells and induce Foxp3(+) regulatory T cells. *Am J Respir Crit Care Med* 179, 344-355. 10.1164/rccm.200804-592OC.
198. de Buhr, M.F., Hedrich, H.J., Westendorf, A.M., Obermeier, F., Hofmann, C., Zschemisch, N.H., Buer, J., Bumann, D., Goyert, S.M., and Bleich, A. (2009). Analysis of Cd14 as a genetic modifier of experimental inflammatory bowel disease (IBD) in mice. *Inflamm Bowel Dis* 15, 1824-1836. 10.1002/ibd.21030.
199. Veldhoen, M., Uyttenhove, C., van Snick, J., Helmby, H., Westendorf, A., Buer, J., Martin, B., Wilhelm, C., and Stockinger, B. (2008). Transforming growth factor-beta 'reprograms' the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset. *Nat Immunol* 9, 1341-1346. 10.1038/ni.1659.
200. Veldhoen, M., Hirota, K., Westendorf, A.M., Buer, J., Dumoutier, L., Renauld, J.C., and Stockinger, B. (2008). The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins. *Nature* 453, 106-109. 10.1038/nature06881.
201. Seifert, O., Bayat, A., Geffers, R., Dienus, K., Buer, J., Lofgren, S., and Matussek, A. (2008). Identification of unique gene expression patterns within different lesional sites of keloids. *Wound Repair Regen* 16, 254-265. 10.1111/j.1524-475X.2007.00343.x.
202. Schenk, U., Westendorf, A.M., Radaelli, E., Casati, A., Ferro, M., Fumagalli, M., Verderio, C., Buer, J., Scanziani, E., and Grassi, F. (2008). Purinergic control of T cell activation by ATP released through pannexin-1 hemichannels. *Sci Signal* 1, ra6. 10.1126/scisignal.1160583.
203. Reinwald, S., Wiethe, C., Westendorf, A.M., Breloer, M., Probst-Kepper, M., Fleischer, B., Steinkasserer, A., Buer, J., and Hansen, W. (2008). CD83 expression in CD4+ T cells modulates inflammation and autoimmunity. *J Immunol* 180, 5890-5897.
204. Nicleleit, I., Zender, S., Sasse, F., Geffers, R., Brandes, G., Sorensen, I., Steinmetz, H., Kubicka, S., Carlomagno, T., Menche, D., Gutgemann, I., Buer, J., Gossler, A., Manns, M.P., Kalesse, M., Frank, R., and Malek, N.P. (2008). Argyrin a reveals a critical role for the tumor suppressor

- protein p27(kip1) in mediating antitumor activities in response to proteasome inhibition. *Cancer Cell* 14, 23-35. 10.1016/j.ccr.2008.05.016.
205. Hansen, W., Westendorf, A.M., and Buer, J. (2008). Regulatory T cells as targets for immunotherapy of autoimmunity and inflammation. *Inflamm Allergy Drug Targets* 7, 217-223.
 206. Haile, L.A., von Wasielewski, R., Gamrekashvili, J., Kruger, C., Bachmann, O., Westendorf, A.M., Buer, J., Liblau, R., Manns, M.P., Korangy, F., and Greten, T.F. (2008). Myeloid-derived suppressor cells in inflammatory bowel disease: a new immunoregulatory pathway. *Gastroenterology* 135, 871-881, 881 e871-875. 10.1053/j.gastro.2008.06.032.
 207. Gustafsson, C., Mjosberg, J., Matussek, A., Geffers, R., Matthiesen, L., Berg, G., Sharma, S., Buer, J., and Ernerudh, J. (2008). Gene expression profiling of human decidual macrophages: evidence for immunosuppressive phenotype. *PLoS One* 3, e2078. 10.1371/journal.pone.0002078.
 208. Ukena, S.N., Singh, A., Dringenberg, U., Engelhardt, R., Seidler, U., Hansen, W., Bleich, A., Bruder, D., Franzke, A., Rogler, G., Suerbaum, S., Buer, J., Gunzer, F., and Westendorf, A.M. (2007). Probiotic *Escherichia coli* Nissle 1917 inhibits leaky gut by enhancing mucosal integrity. *PLoS One* 2, e1308. 10.1371/journal.pone.0001308.
 209. Stecher, B., Robbiani, R., Walker, A.W., Westendorf, A.M., Barthel, M., Kremer, M., Chaffron, S., Macpherson, A.J., Buer, J., Parkhill, J., Dougan, G., von Mering, C., and Hardt, W.D. (2007). *Salmonella enterica* serovar typhimurium exploits inflammation to compete with the intestinal microbiota. *PLoS Biol* 5, 2177-2189. 10.1371/journal.pbio.0050244.
 210. Schrader, A.J., Hegele, A., Olbert, P., Buer, J., Jeron, A., and Hofmann, R. (2007). [Application monitoring of the use of sorafenib in papillary renal cell carcinoma]. *Urologe A* 46, 1291. 10.1007/s00120-007-1500-9.
 211. McMillan, D.J., Geffers, R., Buer, J., Vlamincx, B.J., Sriprakash, K.S., and Chhatwal, G.S. (2007). Variations in the distribution of genes encoding virulence and extracellular proteins in group A streptococcus are largely restricted to 11 genomic loci. *Microbes Infect* 9, 259-270. 10.1016/j.micinf.2006.11.014.
 212. Masse, G.X., Corcuff, E., Decaluwe, H., Bommhardt, U., Lantz, O., Buer, J., and Di Santo, J.P. (2007). gamma(c) cytokines provide multiple homeostatic signals to naive CD4(+) T cells. *Eur J Immunol* 37, 2606-2616. 10.1002/eji.200737234.
 213. Jablonska, J., Dittmar, K.E., Kleinke, T., Buer, J., and Weiss, S. (2007). Essential role of CCL2 in clustering of splenic ERTR-9+ macrophages during infection of BALB/c mice by *Listeria monocytogenes*. *Infect Immun* 75, 462-470. 10.1128/IAI.00443-06.
 214. He, F., Buer, J., Zeng, A.P., and Balling, R. (2007). Dynamic cumulative activity of transcription factors as a mechanism of quantitative gene regulation. *Genome Biol* 8, R181. 10.1186/gb-2007-8-9-r181.
 215. Hansen, W., Westendorf, A.M., Reinwald, S., Bruder, D., Deppenmeier, S., Groebe, L., Probst-Keppler, M., Gruber, A.D., Geffers, R., and Buer, J. (2007). Chronic antigen stimulation in vivo induces a distinct population of antigen-specific Foxp3 CD25 regulatory T cells. *J Immunol* 179, 8059-8068.
 216. Gereke, M., Grobe, L., Prettin, S., Kasper, M., Deppenmeier, S., Gruber, A.D., Enelow, R.I., Buer, J., and Bruder, D. (2007). Phenotypic alterations in type II alveolar epithelial cells in CD4+ T cell mediated lung inflammation. *Respir Res* 8, 47. 10.1186/1465-9921-8-47.
 217. Choudhury, A.R., Ju, Z., Djojotubroto, M.W., Schienke, A., Lechel, A., Schaetzlein, S., Jiang, H., Stepczynska, A., Wang, C., Buer, J., Lee, H.W., von Zglinicki, T., Ganser, A., Schirmacher, P.,

- Nakauchi, H., and Rudolph, K.L. (2007). Cdkn1a deletion improves stem cell function and lifespan of mice with dysfunctional telomeres without accelerating cancer formation. *Nat Genet* 39, 99-105. 10.1038/ng1937.
218. Bohn, G., Allroth, A., Brandes, G., Thiel, J., Glocker, E., Schaffer, A.A., Rathinam, C., Taub, N., Teis, D., Zeidler, C., Dewey, R.A., Geffers, R., Buer, J., Huber, L.A., Welte, K., Grimbacher, B., and Klein, C. (2007). A novel human primary immunodeficiency syndrome caused by deficiency of the endosomal adaptor protein p14. *Nat Med* 13, 38-45. 10.1038/nm1528.
 219. Westendorf, A.M., Fleissner, D., Deppenmeier, S., Gruber, A.D., Bruder, D., Hansen, W., Liblau, R., and Buer, J. (2006). Autoimmune-mediated intestinal inflammation-impact and regulation of antigen-specific CD8+ T cells. *Gastroenterology* 131, 510-524. 10.1053/j.gastro.2006.05.015.
 220. Westendorf, A.M., Bruder, D., Hansen, W., and Buer, J. (2006). Intestinal epithelial antigen induces CD4+ T cells with regulatory phenotype in a transgenic autoimmune mouse model. *Ann N Y Acad Sci* 1072, 401-406. 10.1196/annals.1326.035.
 221. Wendt, K., Wilk, E., Buyny, S., Buer, J., Schmidt, R.E., and Jacobs, R. (2006). Gene and protein characteristics reflect functional diversity of CD56dim and CD56bright NK cells. *J Leukoc Biol* 80, 1529-1541. 10.1189/jlb.0306191.
 222. Veldman, C., Pahl, A., Beissert, S., Hansen, W., Buer, J., Dieckmann, D., Schuler, G., and Hertl, M. (2006). Inhibition of the transcription factor Foxp3 converts desmoglein 3-specific type 1 regulatory T cells into Th2-like cells. *J Immunol* 176, 3215-3222.
 223. Timmerbeul, I., Garrett-Engele, C.M., Kossatz, U., Chen, X., Firpo, E., Grunwald, V., Kamino, K., Wilkens, L., Lehmann, U., Buer, J., Geffers, R., Kubicka, S., Manns, M.P., Porter, P.L., Roberts, J.M., and Malek, N.P. (2006). Testing the importance of p27 degradation by the SCFskp2 pathway in murine models of lung and colon cancer. *Proc Natl Acad Sci U S A* 103, 14009-14014. 10.1073/pnas.0606316103.
 224. Schrader, A.J., Varga, Z., Pfoertner, S., Goelden, U., Buer, J., and Hofmann, R. (2006). Treatment targeted at vascular endothelial growth factor: a promising approach to managing metastatic kidney cancer. *BJU Int* 97, 461-465. 10.1111/j.1464-410X.2006.05873.x.
 225. Pfoertner, S., Jeron, A., Probst-Kepper, M., Guzman, C.A., Hansen, W., Westendorf, A.M., Toepfer, T., Schrader, A.J., Franzke, A., Buer, J., and Geffers, R. (2006). Signatures of human regulatory T cells: an encounter with old friends and new players. *Genome Biol* 7, R54. 10.1186/gb-2006-7-7-r54.
 226. Ocklenburg, F., Moharreggh-Khiabani, D., Geffers, R., Janke, V., Pfoertner, S., Garritsen, H., Groebe, L., Klemptner, J., Dittmar, K.E., Weiss, S., Buer, J., and Probst-Kepper, M. (2006). UBD, a downstream element of FOXP3, allows the identification of LGALS3, a new marker of human regulatory T cells. *Lab Invest* 86, 724-737. 10.1038/labinvest.3700432.
 227. Nalca, Y., Jansch, L., Bredenbruch, F., Geffers, R., Buer, J., and Haussler, S. (2006). Quorum-sensing antagonistic activities of azithromycin in *Pseudomonas aeruginosa* PAO1: a global approach. *Antimicrob Agents Chemother* 50, 1680-1688. 10.1128/AAC.50.5.1680-1688.2006.
 228. McMillan, D.J., Beiko, R.G., Geffers, R., Buer, J., Schouls, L.M., Vlamincx, B.J., Wannet, W.J., Sriprakash, K.S., and Chhatwal, G.S. (2006). Genes for the majority of group a streptococcal virulence factors and extracellular surface proteins do not confer an increased propensity to cause invasive disease. *Clin Infect Dis* 43, 884-891. 10.1086/507537.
 229. Kaps, C., Frauenschuh, S., Endres, M., Ringe, J., Haisch, A., Lauber, J., Buer, J., Krenn, V., Haupl, T., Burmester, G.R., and Sittinger, M. (2006). Gene expression profiling of human

- articular cartilage grafts generated by tissue engineering. *Biomaterials* 27, 3617-3630. 10.1016/j.biomaterials.2006.02.017.
230. Hansen, W., Loser, K., Westendorf, A.M., Bruder, D., Pfoertner, S., Siewert, C., Huehn, J., Beissert, S., and Buer, J. (2006). G protein-coupled receptor 83 overexpression in naive CD4⁺CD25⁻ T cells leads to the induction of Foxp3⁺ regulatory T cells in vivo. *J Immunol* 177, 209-215.
 231. Garbe, A.I., Vermeer, B., Gamrekashvili, J., von Wasielewski, R., Greten, F.R., Westendorf, A.M., Buer, J., Schmid, R.M., Manns, M.P., Korangy, F., and Greten, T.F. (2006). Genetically induced pancreatic adenocarcinoma is highly immunogenic and causes spontaneous tumor-specific immune responses. *Cancer Res* 66, 508-516. 10.1158/0008-5472.CAN-05-2383.
 232. Fritzsching, B., Oberle, N., Pauly, E., Geffers, R., Buer, J., Poschl, J., Krammer, P., Linderkamp, O., and Suri-Payer, E. (2006). Naive regulatory T cells: a novel subpopulation defined by resistance toward CD95L-mediated cell death. *Blood* 108, 3371-3378. 10.1182/blood-2006-02-005660.
 233. Franzke, A., Koenecke, C., Geffers, R., Piao, W., Hunger, J.K., Ganser, A., and Buer, J. (2006). Classical Hodgkin's lymphoma: molecular evidence for specific alterations in circulating T lymphocytes. *Tumour Biol* 27, 329-333. 10.1159/000096151.
 234. Franzke, A., Hunger, J.K., Dittmar, K.E., Ganser, A., and Buer, J. (2006). Regulatory T-cells in the control of immunological diseases. *Ann Hematol* 85, 747-758. 10.1007/s00277-006-0117-1.
 235. Franzke, A., Geffers, R., Hunger, J.K., Pfortner, S., Piao, W., Ivanyi, P., Grosse, J., Probst-Keppler, M., Ganser, A., and Buer, J. (2006). Identification of novel regulators in T-cell differentiation of aplastic anemia patients. *BMC Genomics* 7, 263. 10.1186/1471-2164-7-263.
 236. de Buhr, M.F., Mahler, M., Geffers, R., Hansen, W., Westendorf, A.M., Lauber, J., Buer, J., Schlegelberger, B., Hedrich, H.J., and Bleich, A. (2006). Cd14, Gbp1, and Pla2g2a: three major candidate genes for experimental IBD identified by combining QTL and microarray analyses. *Physiol Genomics* 25, 426-434. 10.1152/physiolgenomics.00022.2005.
 237. Bredenbruch, F., Geffers, R., Nimtz, M., Buer, J., and Haussler, S. (2006). The *Pseudomonas aeruginosa* quinolone signal (PQS) has an iron-chelating activity. *Environ Microbiol* 8, 1318-1329. 10.1111/j.1462-2920.2006.01025.x.
 238. Blumenthal, A., Ehlers, S., Lauber, J., Buer, J., Lange, C., Goldmann, T., Heine, H., Brandt, E., and Reiling, N. (2006). The Wingless homolog WNT5A and its receptor Frizzled-5 regulate inflammatory responses of human mononuclear cells induced by microbial stimulation. *Blood* 108, 965-973. 10.1182/blood-2005-12-5046.
 239. Wiemann, S.U., Satyanarayana, A., Buer, J., Kamino, K., Manns, M.P., and Rudolph, K.L. (2005). Contrasting effects of telomere shortening on organ homeostasis, tumor suppression, and survival during chronic liver damage. *Oncogene* 24, 1501-1509. 10.1038/sj.onc.1208308.
 240. Westendorf, A.M., Templin, M., Geffers, R., Deppenmeier, S., Gruber, A.D., Probst-Keppler, M., Hansen, W., Liblau, R.S., Gunzer, F., Bruder, D., and Buer, J. (2005). CD4⁺ T cell mediated intestinal immunity: chronic inflammation versus immune regulation. *Gut* 54, 60-69. 10.1136/gut.2003.037663.
 241. Westendorf, A.M., Gunzer, F., Deppenmeier, S., Tapadar, D., Hunger, J.K., Schmidt, M.A., Buer, J., and Bruder, D. (2005). Intestinal immunity of *Escherichia coli* NISSLE 1917: a safe carrier for therapeutic molecules. *FEMS Immunol Med Microbiol* 43, 373-384. 10.1016/j.femsim.2004.10.023.

242. Ukena, S.N., Westendorf, A.M., Hansen, W., Rohde, M., Geffers, R., Coldewey, S., Suerbaum, S., Buer, J., and Gunzer, F. (2005). The host response to the probiotic *Escherichia coli* strain Nissle 1917: specific up-regulation of the proinflammatory chemokine MCP-1. *BMC Med Genet* 6, 43. 10.1186/1471-2350-6-43.
243. Sun, J., Gunzer, F., Westendorf, A.M., Buer, J., Scharfe, M., Jarek, M., Gossling, F., Blocker, H., and Zeng, A.P. (2005). Genomic peculiarity of coding sequences and metabolic potential of probiotic *Escherichia coli* strain Nissle 1917 inferred from raw genome data. *J Biotechnol* 117, 147-161. 10.1016/j.jbiotec.2005.01.008.
244. Salunkhe, P., Topfer, T., Buer, J., and Tummler, B. (2005). Genome-wide transcriptional profiling of the steady-state response of *Pseudomonas aeruginosa* to hydrogen peroxide. *J Bacteriol* 187, 2565-2572. 10.1128/JB.187.8.2565-2572.2005.
245. Rharbaoui, F., Bruder, D., Vidakovic, M., Ebensen, T., Buer, J., and Guzman, C.A. (2005). Characterization of a B220+ lymphoid cell subpopulation with immune modulatory functions in nasal-associated lymphoid tissues. *J Immunol* 174, 1317-1324.
246. Rathinam, C., Geffers, R., Yucel, R., Buer, J., Welte, K., Moroy, T., and Klein, C. (2005). The transcriptional repressor Gfi1 controls STAT3-dependent dendritic cell development and function. *Immunity* 22, 717-728. 10.1016/j.immuni.2005.04.007.
247. Priebe-Richter, C., Ivanyi, P., Buer, J., Langer, F., Lotz, J., Hertenstein, B., Ganzer, A., and Franzke, A. (2005). Inflammatory pseudotumor of the lung following invasive aspergillosis in a patient with chronic graft-vs.-host disease. *Eur J Haematol* 75, 68-72. 10.1111/j.1600-0609.2005.00478.x.
248. Pfoertner, S., Goelden, U., Hansen, W., Toepfer, T., Geffers, R., Ukena, S.N., von Knobloch, R., Hofmann, R., Buer, J., and Schrader, A.J. (2005). Cellular retinoic acid binding protein I: expression and functional influence in renal cell carcinoma. *Tumour Biol* 26, 313-323. 10.1159/000089262.
249. Matussek, A., Strindhall, J., Stark, L., Rohde, M., Geffers, R., Buer, J., Kihlstrom, E., Lindgren, P.E., and Lofgren, S. (2005). Infection of human endothelial cells with *Staphylococcus aureus* induces transcription of genes encoding an innate immunity response. *Scand J Immunol* 61, 536-544. 10.1111/j.1365-3083.2005.01597.x.
250. Loser, K., Hansen, W., Apelt, J., Balkow, S., Buer, J., and Beissert, S. (2005). In vitro-generated regulatory T cells induced by Foxp3-retrovirus infection control murine contact allergy and systemic autoimmunity. *Gene Ther* 12, 1294-1304. 10.1038/sj.gt.3302567.
251. Lechel, A., Satyanarayana, A., Ju, Z., Plentz, R.R., Schaetzlein, S., Rudolph, C., Wilkens, L., Wiemann, S.U., Saretzki, G., Malek, N.P., Manns, M.P., Buer, J., and Rudolph, K.L. (2005). The cellular level of telomere dysfunction determines induction of senescence or apoptosis in vivo. *EMBO Rep* 6, 275-281. 10.1038/sj.embor.7400352.
252. Juhas, M., Wiehlmann, L., Salunkhe, P., Lauber, J., Buer, J., and Tummler, B. (2005). GeneChip expression analysis of the VqsR regulon of *Pseudomonas aeruginosa* TB. *FEMS Microbiol Lett* 242, 287-295. 10.1016/j.femsle.2004.11.020.
253. Goelden, U., Ukena, S.N., Pfoertner, S., Hofmann, R., Buer, J., and Schrader, A.J. (2005). RAR-beta(1) overexpression in chromophobe renal cell carcinoma: a novel target for therapeutic intervention? *Exp Oncol* 27, 220-224.
254. Goelden, U., Pfoertner, S., Hansen, W., Toepfer, T., von Knobloch, R., Hofmann, R., Buer, J., and Schrader, A.J. (2005). Expression and functional influence of cellular retinoic acid-binding protein II in renal cell carcinoma. *Urol Int* 75, 269-276. 10.1159/000087807.

255. Buer, J., Westendorf, A.M., Zeng, A.-P., He, F., Hansen, W., and Probst-Kepper, M. (2005). Mechanisms of central and peripheral T-cell tolerance: An update. *Transfus Med Hemother* 32, 384-399.
256. Bruder, D., Westendorf, A.M., Hansen, W., Prettin, S., Gruber, A.D., Qian, Y., von Boehmer, H., Mahnke, K., and Buer, J. (2005). On the edge of autoimmunity: T-cell stimulation by steady-state dendritic cells prevents autoimmune diabetes. *Diabetes* 54, 3395-3401.
257. Blumenthal, A., Lauber, J., Hoffmann, R., Ernst, M., Keller, C., Buer, J., Ehlers, S., and Reiling, N. (2005). Common and unique gene expression signatures of human macrophages in response to four strains of *Mycobacterium avium* that differ in their growth and persistence characteristics. *Infect Immun* 73, 3330-3341. 10.1128/IAI.73.6.3330-3341.2005.
258. Walter, U., Scherbaum, W.A., Walter, U., and Buer, J. (2004). MHC class II expression by beta cells in Type 1 diabetes: promoting or inhibiting the autoimmune process? A reply to D. W. R. Gray. *Diabetologia* 47, 1641-1642. 10.1007/s00125-004-1476-6.
259. von Gotz, F., Haussler, S., Jordan, D., Saravanamuthu, S.S., Wehmhoner, D., Strussmann, A., Lauber, J., Attree, I., Buer, J., Tummler, B., and Steinmetz, I. (2004). Expression analysis of a highly adherent and cytotoxic small colony variant of *Pseudomonas aeruginosa* isolated from a lung of a patient with cystic fibrosis. *J Bacteriol* 186, 3837-3847. 10.1128/JB.186.12.3837-3847.2004.
260. Schrader, A.J., von Knobloch, R., Heidenreich, A., Buer, J., and Hofmann, R. (2004). Application of retinoids in the treatment of renal cell carcinoma--a futile effort? *Anticancer Drugs* 15, 819-824.
261. Satyanarayana, A., Greenberg, R.A., Schaetzlein, S., Buer, J., Masutomi, K., Hahn, W.C., Zimmermann, S., Martens, U., Manns, M.P., and Rudolph, K.L. (2004). Mitogen stimulation cooperates with telomere shortening to activate DNA damage responses and senescence signaling. *Mol Cell Biol* 24, 5459-5474. 10.1128/MCB.24.12.5459-5474.2004.
262. Satyanarayana, A., Geffers, R., Manns, M.P., Buer, J., and Rudolph, K.L. (2004). Gene expression profile at the G1/S transition of liver regeneration after partial hepatectomy in mice. *Cell Cycle* 3, 1405-1417. 10.4161/cc.3.11.1212.
263. Saravanamuthu, S.S., von Gotz, F., Salunkhe, P., Chozhavendan, R., Geffers, R., Buer, J., Tummler, B., and Steinmetz, I. (2004). Evidence for polyadenylated mRNA in *Pseudomonas aeruginosa*. *J Bacteriol* 186, 7015-7018. 10.1128/JB.186.20.7015-7018.2004.
264. Rharbaoui, F., Westendorf, A., Link, C., Felk, S., Buer, J., Gunzer, M., and Guzman, C.A. (2004). The Mycoplasma-derived macrophage-activating 2-kilodalton lipopeptide triggers global immune activation on nasal mucosa-associated lymphoid tissues. *Infect Immun* 72, 6978-6986. 10.1128/IAI.72.12.6978-6986.2004.
265. Ma, H.W., Kumar, B., Ditzges, U., Gunzer, F., Buer, J., and Zeng, A.P. (2004). An extended transcriptional regulatory network of *Escherichia coli* and analysis of its hierarchical structure and network motifs. *Nucleic Acids Res* 32, 6643-6649. 10.1093/nar/gkh1009.
266. Ma, H.W., Buer, J., and Zeng, A.P. (2004). Hierarchical structure and modules in the *Escherichia coli* transcriptional regulatory network revealed by a new top-down approach. *BMC Bioinformatics* 5, 199. 10.1186/1471-2105-5-199.
267. Kossatz, U., Dietrich, N., Zender, L., Buer, J., Manns, M.P., and Malek, N.P. (2004). Skp2-dependent degradation of p27kip1 is essential for cell cycle progression. *Genes Dev* 18, 2602-2607. 10.1101/gad.321004.

268. Keller, C., Lauber, J., Blumenthal, A., Buer, J., and Ehlers, S. (2004). Resistance and susceptibility to tuberculosis analysed at the transcriptome level: lessons from mouse macrophages. *Tuberculosis (Edinb)* 84, 144-158. 10.1016/j.tube.2003.12.003.
269. Huehn, J., Siegmund, K., Lehmann, J.C., Siewert, C., Haubold, U., Feuerer, M., Debes, G.F., Lauber, J., Frey, O., Przybylski, G.K., Niesner, U., de la Rosa, M., Schmidt, C.A., Brauer, R., Buer, J., Scheffold, A., and Hamann, A. (2004). Developmental stage, phenotype, and migration distinguish naive- and effector/memory-like CD4⁺ regulatory T cells. *J Exp Med* 199, 303-313. 10.1084/jem.20031562.
270. Hansen, W., and Buer, J. (2004). Role of regulatory T cells for the outcome of allo- and autoimmune responses. *Transfus Med Hemother* 31, 322-331.
271. Eschbach, M., Schreiber, K., Trunk, K., Buer, J., Jahn, D., and Schobert, M. (2004). Long-term anaerobic survival of the opportunistic pathogen *Pseudomonas aeruginosa* via pyruvate fermentation. *J Bacteriol* 186, 4596-4604. 10.1128/JB.186.14.4596-4604.2004.
272. Bruder, D., Westendorf, A.M., Geffers, R., Gruber, A.D., Gereke, M., Enelow, R.I., and Buer, J. (2004). CD4 T Lymphocyte-mediated lung disease: steady state between pathological and tolerogenic immune reactions. *Am J Respir Crit Care Med* 170, 1145-1152. 10.1164/rccm.200404-464OC.
273. Bruder, D., Probst-Keppler, M., Westendorf, A.M., Geffers, R., Beissert, S., Loser, K., von Boehmer, H., Buer, J., and Hansen, W. (2004). Neuropilin-1: a surface marker of regulatory T cells. *Eur J Immunol* 34, 623-630. 10.1002/eji.200324799.
274. Bohn, E., Muller, S., Lauber, J., Geffers, R., Speer, N., Spieth, C., Krejci, J., Manncke, B., Buer, J., Zell, A., and Autenrieth, I.B. (2004). Gene expression patterns of epithelial cells modulated by pathogenicity factors of *Yersinia enterocolitica*. *Cell Microbiol* 6, 129-141.
275. Wuestefeld, T., Klein, C., Streetz, K.L., Betz, U., Lauber, J., Buer, J., Manns, M.P., Muller, W., and Trautwein, C. (2003). Interleukin-6/glycoprotein 130-dependent pathways are protective during liver regeneration. *J Biol Chem* 278, 11281-11288. 10.1074/jbc.M208470200.
276. Walter, U., Toepfer, T., Dittmar, K.E., Kretschmer, K., Lauber, J., Weiss, S., Servos, G., Lechner, O., Scherbaum, W.A., Bornstein, S.R., Von Boehmer, H., and Buer, J. (2003). Pancreatic NOD beta cells express MHC class II protein and the frequency of I-A(g7) mRNA-expressing beta cells strongly increases during progression to autoimmune diabetes. *Diabetologia* 46, 1106-1114. 10.1007/s00125-003-1164-y.
277. Schrader, A.J., Lauber, J., Lechner, O., Heidenreich, A., Hofmann, R., and Buer, J. (2003). Application of real-time reverse transcriptase-polymerase chain reaction in urological oncology. *J Urol* 169, 1858-1864. 10.1097/01.ju.0000047363.03411.6b.
278. Satyanarayana, A., Wiemann, S.U., Buer, J., Lauber, J., Dittmar, K.E., Wuestefeld, T., Blasco, M.A., Manns, M.P., and Rudolph, K.L. (2003). Telomere shortening impairs organ regeneration by inhibiting cell cycle re-entry of a subpopulation of cells. *EMBO J* 22, 4003-4013. 10.1093/emboj/cdg367.
279. Samson, S.I., Richard, O., Tavian, M., Ranson, T., Vosshenrich, C.A., Colucci, F., Buer, J., Grosveld, F., Godin, I., and Di Santo, J.P. (2003). GATA-3 promotes maturation, IFN-gamma production, and liver-specific homing of NK cells. *Immunity* 19, 701-711.
280. Pulz, M., Matussek, A., Monazahian, M., Tittel, A., Nikolic, E., Hartmann, M., Bellin, T., Buer, J., and Gunzer, F. (2003). Comparison of a shiga toxin enzyme-linked immunosorbent assay and two types of PCR for detection of shiga toxin-producing *Escherichia coli* in human stool specimens. *J Clin Microbiol* 41, 4671-4675.

281. Matussek, A., Lauber, J., Bergau, A., Hansen, W., Rohde, M., Dittmar, K.E., Gunzer, M., Mengel, M., Gatzlaff, P., Hartmann, M., Buer, J., and Gunzer, F. (2003). Molecular and functional analysis of Shiga toxin-induced response patterns in human vascular endothelial cells. *Blood* 102, 1323-1332. 10.1182/blood-2002-10-3301.
282. Franzke, A., Piao, W., Lauber, J., Gatzlaff, P., Konecke, C., Hansen, W., Schmitt-Thomsen, A., Hertenstein, B., Buer, J., and Ganser, A. (2003). G-CSF as immune regulator in T cells expressing the G-CSF receptor: implications for transplantation and autoimmune diseases. *Blood* 102, 734-739. 10.1182/blood-2002-04-1200.
283. Buer, J., and Balling, R. (2003). Mice, microbes and models of infection. *Nat Rev Genet* 4, 195-205. 10.1038/nrg1019.
284. Sechi, A.S., Buer, J., Wehland, J., and Probst-Kepper, M. (2002). Changes in actin dynamics at the T-cell/APC interface: implications for T-cell anergy? *Immunol Rev* 189, 98-110.
285. Schrader, A.J., Lechner, O., Templin, M., Dittmar, K.E., Machtens, S., Mengel, M., Probst-Kepper, M., Franzke, A., Wollensak, T., Gatzlaff, P., Atzpodien, J., Buer, J., and Lauber, J. (2002). CXCR4/CXCL12 expression and signalling in kidney cancer. *Br J Cancer* 86, 1250-1256. 10.1038/sj.bjc.6600221.
286. Salunkhe, P., von Götz, F., Wiehlmann, L., Lauber, J., Buer, J., and Tümmler, B. (2002). GeneChip expression analysis of the response of *Pseudomonas aeruginosa* to Paraquat-induced superoxide stress. *Genome Letters* 4, 165-174.
287. Lechner, O., Bruder, D., Lauber, J., and Buer, J. (2002). Anerge T-Zellen: Immunregulatoren für die Klinik. *Die gelben Hefte* 42, 17-26.
288. Garritsen, H.S.P., Macke, L., Lauber, J., Buer, J., Pagelow, U., Rohde, M., Hannig, H., Pies, A., Wormann, B., Lindenmaier, W., and Dittmar, K.E.J. (2002). Genetically modified dendritic cells expressing two melanoma specific antigens simultaneously. *Transfusion* 42, 505-505.
289. Ehlers, S., Lehmann, J., Muller, K., Laskay, T., Buer, J., and Lauber, J. (2002). Measuring immune responses in vivo. *Method Microbiol* 32, 403-431.
290. Lechner, O., Lauber, J., Franzke, A., Sarukhan, A., von Boehmer, H., and Buer, J. (2001). Fingerprints of anergic T cells. *Curr Biol* 11, 587-595.
291. Hess, S., Rheinheimer, C., Tidow, F., Bartling, G., Kaps, C., Lauber, J., Buer, J., and Klos, A. (2001). The reprogrammed host: Chlamydia trachomatis-induced up-regulation of glycoprotein 130 cytokines, transcription factors, and antiapoptotic genes. *Arthritis Rheum* 44, 2392-2401.
292. Franzke, A., Buer, J., Probst-Kepper, M., Lindig, C., Framzle, M., Schrader, A.J., Ganser, A., and Atzpodien, J. (2001). HLA phenotype and cytokine-induced tumor control in advanced renal cell cancer. *Cancer Biother Radiopharm* 16, 401-409. 10.1089/108497801753354302.
293. Felske, A., Pauling, B.V., von Canstein, H.F., Li, Y., Lauber, J., Buer, J., and Wagner-Dobler, I. (2001). Detection of small sequence differences using competitive PCR: molecular monitoring of genetically improved, mercury-reducing bacteria. *Biotechniques* 30, 142-148.
294. Walter, U., Franzke, A., Sarukhan, A., Zober, C., von Boehmer, H., Buer, J., and Lechner, O. (2000). Monitoring gene expression of TNFR family members by beta-cells during development of autoimmune diabetes. *Eur J Immunol* 30, 1224-1232.
295. Schrader, A.J., Probst-Kepper, M., Grosse, J., Kunter, U., Schenk, F., Franzke, A., Atzpodien, J., and Buer, J. (2000). Molecular and prognostic classification of advanced melanoma: a multi-marker microcontamination assay of peripheral blood stem cells. *Melanoma Res* 10, 355-362.

296. Schrader, A.J., Probst-Kepper, M., Grosse, J., Kunter, U., Franzke, A., Sel, S., Atzpodien, E., and Buer, J. (2000). Tumour microdissemination and survival in metastatic melanoma. *Anticancer Res* 20, 3619-3624.
297. Oevermann, K., Buer, J., Hoffmann, R., Franzke, A., Schrader, A., Patzelt, T., Kirchner, H., and Atzpodien, J. (2000). Capecitabine in the treatment of metastatic renal cell carcinoma. *Br J Cancer* 83, 583-587. 10.1054/bjoc.2000.1340.
298. Wittke, F., Hoffmann, R., Buer, J., Dallmann, I., Oevermann, K., Sel, S., Wandert, T., Ganser, A., and Atzpodien, J. (1999). Interleukin 10 (IL-10): an immunosuppressive factor and independent predictor in patients with metastatic renal cell carcinoma. *Br J Cancer* 79, 1182-1184. 10.1038/sj.bjc.6690189.
299. von Boehmer, H., Aifantis, I., Feinberg, J., Lechner, O., Saint-Ruf, C., Walter, U., Buer, J., and Azogui, O. (1999). Pleiotropic changes controlled by the pre-T-cell receptor. *Curr Opin Immunol* 11, 135-142.
300. Hoffmann, R., Franzke, A., Buer, J., Sel, S., Oevermann, K., Duensing, A., Probst, M., Duensing, S., Kirchner, H., Ganser, A., and Atzpodien, J. (1999). Prognostic impact of in vivo soluble cell adhesion molecules in metastatic renal cell carcinoma. *Br J Cancer* 79, 1742-1745. 10.1038/sj.bjc.6690277.
301. Franzke, A., Peest, D., Probst-Kepper, M., Buer, J., Kirchner, G.I., Brabant, G., Kirchner, H., Ganser, A., and Atzpodien, J. (1999). Autoimmunity resulting from cytokine treatment predicts long-term survival in patients with metastatic renal cell cancer. *J Clin Oncol* 17, 529-533. 10.1200/JCO.1999.17.2.529.
302. Atzpodien, J., Buer, J., Sel, S., Janssen, J., and Oevermann, K. (1999). Chemoimmunotherapy in the systemic treatment of advanced renal carcinoma. *Urologe A* 38, 474-478.
303. von Boehmer, H., Aifantis, I., Azogui, O., Feinberg, J., Saint-Ruf, C., Zober, C., Garcia, C., and Buer, J. (1998). Crucial function of the pre-T-cell receptor (TCR) in TCR beta selection, TCR beta allelic exclusion and alpha beta versus gamma delta lineage commitment. *Immunol Rev* 165, 111-119.
304. Sarukhan, A., Lanoue, A., Franzke, A., Brousse, N., Buer, J., and von Boehmer, H. (1998). Changes in function of antigen-specific lymphocytes correlating with progression towards diabetes in a transgenic model. *EMBO J* 17, 71-80. 10.1093/emboj/17.1.71.
305. Kirchner, G.I., Franzke, A., Buer, J., Beil, W., Probst-Kepper, M., Wittke, F., Overmann, K., Lassmann, S., Hoffmann, R., Kirchner, H., Ganser, A., and Atzpodien, J. (1998). Pharmacokinetics of recombinant human interleukin-2 in advanced renal cell carcinoma patients following subcutaneous application. *Br J Clin Pharmacol* 46, 5-10.
306. Hoffmann, R., Muller, I., Neuber, K., Lassmann, S., Buer, J., Probst, M., Oevermann, K., Franzke, A., Kirchner, H., Ganser, A., and Atzpodien, J. (1998). Risk and outcome in metastatic malignant melanoma patients receiving DTIC, cisplatin, BCNU and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha2a. *Br J Cancer* 78, 1076-1080.
307. Franzke, A., Probst-Kepper, M., Buer, J., Duensing, S., Hoffmann, R., Wittke, F., Volkenandt, M., Ganser, A., and Atzpodien, J. (1998). Elevated pretreatment serum levels of soluble vascular cell adhesion molecule 1 and lactate dehydrogenase as predictors of survival in cutaneous metastatic malignant melanoma. *Br J Cancer* 78, 40-45.
308. Buer, J., Lanoue, A., Franzke, A., Garcia, C., von Boehmer, H., and Sarukhan, A. (1998). Interleukin 10 secretion and impaired effector function of major histocompatibility complex class II-restricted T cells anergized in vivo. *J Exp Med* 187, 177-183.

309. Aifantis, I., Azogui, O., Feinberg, J., Saint-Ruf, C., Buer, J., and von Boehmer, H. (1998). On the role of the pre-T cell receptor in alphabeta versus gammadelta T lineage commitment. *Immunity* 9, 649-655.
310. Probst-Kepper, M., Schrader, A., Buer, J., Grosse, J., Volkenandt, M., Illiger, H.J., Metzner, B., Kadar, J., Duensing, S., Hertenstein, B., Ganzer, A., and Atzpodien, J. (1997). Detection of melanoma cells in peripheral blood stem cell harvests of patients with progressive metastatic malignant melanoma. *Br J Haematol* 98, 488-490.
311. Buer, J., Probst, M., Franzke, A., Duensing, S., Haindl, J., Volkenandt, M., Wittke, F., Hoffmann, R., Ganzer, A., and Atzpodien, J. (1997). Elevated serum levels of S100 and survival in metastatic malignant melanoma. *Br J Cancer* 75, 1373-1376.
312. Buer, J., Probst, M., Duensing, S., Koditz, H., Franzke, A., Dallmann, I., Ganzer, A., and Atzpodien, J. (1997). Clinical and in vitro response to 13-cis-retinoic acid in interferon-alpha resistant renal cell carcinoma. *Cancer Biother Radiopharm* 12, 143-147. 10.1089/cbr.1997.12.143.
313. Buer, J., Aifantis, I., DiSanto, J.P., Fehling, H.J., and von Boehmer, H. (1997). T-cell development in the absence of the pre-T-cell receptor. *Immunol Lett* 57, 5-8.
314. Buer, J., Aifantis, I., DiSanto, J.P., Fehling, H.J., and von Boehmer, H. (1997). Role of different T cell receptors in the development of pre-T cells. *J Exp Med* 185, 1541-1547.
315. Aifantis, I., Buer, J., von Boehmer, H., and Azogui, O. (1997). Essential role of the pre-T cell receptor in allelic exclusion of the T cell receptor beta locus. *Immunity* 7, 601-607.
316. Kunter, U., Buer, J., Probst, M., Duensing, S., Dallmann, I., Grosse, J., Kirchner, H., Schluepen, E.M., Volkenandt, M., Ganzer, A., and Atzpodien, J. (1996). Peripheral blood tyrosinase messenger RNA detection and survival in malignant melanoma. *J Natl Cancer Inst* 88, 590-594.
317. Duensing, S., van den Berg-de Ruitter, E., Storkel, S., Kirchner, H., Hanninen, E.L., Buer, J., Poliwoda, H., and Atzpodien, J. (1996). Cytogenetic studies in renal cell carcinoma patients receiving low-dose recombinant interleukin-2-based immunotherapy. *Tumour Biol* 17, 27-33.
318. Duensing, S., Brevis Nunez, F., Meyer, N., Anastassiou, G., Nasarek, A., Grosse, J., Buer, J., Probst, M., Ganzer, A., and Alzpodien, J. (1996). Exposure to vinblastine modulates beta 1 integrin expression and in vitro binding to extracellular matrix molecules in a human renal carcinoma cell line. *Invasion Metastasis* 16, 65-72.
319. Deckert, M., Franzke, A., Buer, J., Probst, M., Duensing, S., Lopez-Haenninen, E., Kirchner, H., Poliwoda, H., and Atzpodien, J. (1996). Linomide and interleukin-2 in patients with advanced renal cell carcinoma. *Cancer Biother Radiopharm* 11, 319-324. 10.1089/cbr.1996.11.319.
320. Probst, M., Buer, J., and Atzpodien, J. (1995). Genetic abnormalities during transition from *Helicobacter-pylori*-associated gastritis to low-grade MALToma. *Lancet* 345, 723-724.
321. Meffert, M., Schomburg, A., Hanninen, E.L., Menzel, T., Vocke, S., Dallmann, I., Grosse, J., Duensing, S., Buer, J., Kirchner, H., and et al. (1995). In vivo tumor necrosis factor-alpha as indicator of biologic and clinical response to low-dose SC recombinant interleukin 2. *Anticancer Res* 15, 127-132.
322. Buer, J., Probst, M., Ganzer, A., and Atzpodien, J. (1995). Response to 13-cis-retinoic acid plus interferon alfa-2a in two patients with therapy-refractory advanced renal cell carcinoma. *J Clin Oncol* 13, 2679-2680. 10.1200/JCO.1995.13.10.2679.
323. Buer, J., Probst, M., and Atzpodien, J. (1995). Molecular diagnosis of neoplasms. *N Engl J Med* 333, 193-194. 10.1056/NEJM199507203330314.

- 324. Buer, J., Hilse, R., Dallmann, I., Grosse, J., Kirchner, H., Zorn, U., Hanninen, E.L., Franzke, A., Duensing, S., Poliwoda, H., and et al. (1995). Lymphocyte-conditioned medium in combination with interleukin-2 effectively induces antitumour autoimmunity by adoptive transfer of short activated killer (SHAK) cells. *Cytokines Mol Ther* 1, 39-46.
- 325. Atzpodien, J., Kirchner, H., Duensing, S., Lopez Hanninen, E., Franzke, A., Buer, J., Probst, M., Anton, P., and Poliwoda, H. (1995). Biochemotherapy of advanced metastatic renal-cell carcinoma: results of the combination of interleukin-2, alpha-interferon, 5-fluorouracil, vinblastine, and 13-cis-retinoic acid. *World J Urol* 13, 174-177.
- 326. Meffert, M., Hanninen, E.L., Menzel, T., Schomburg, A., Duensing, S., Dallmann, I., Grosse, J., Vocke, S., Buer, J., Deckert, M., and et al. (1994). In vivo time and dose dependency of interleukin-6 secretion in response to low-dose subcutaneous recombinant interleukin-2. *Cancer Biother* 9, 307-316.
- 327. Koch, O.M., Volkenandt, M., Goker, E., Buer, J., Probst, M., Banerjee, D., Danenberg, P.V., and Bertino, J.R. (1994). Molecular detection and characterization of clonal cell populations in acute lymphocytic leukemia by analysis of conformational polymorphisms of cRNA molecules of rearranged T-cell-receptor-gamma and immunoglobulin heavy-chain genes. *Leukemia* 8, 946-952.
- 328. Koch, O.M., Probst, M., Tiemann, M., Jakob, I., Volkenandt, M., Wienecke, R., Buer, J., Atzpodien, J., Lenz, H.J., Danenberg, P.V., and et al. (1994). Detection of clonal T-cell populations in gastrointestinal lymphomas by analysis of cRNA conformational polymorphisms of rearranged T-cell-receptor-gamma genes. *Br J Haematol* 86, 316-321.
- 329. Duensing, S., Dallmann, I., Grosse, J., Buer, J., Lopez Hanninen, E., Deckert, M., Storkel, S., Kirchner, H., Poliwoda, H., and Atzpodien, J. (1994). Immunocytochemical detection of P-glycoprotein: initial expression correlates with survival in renal cell carcinoma patients. *Oncology* 51, 309-313. 10.1159/000227355.
- 330. Buer, J., Kirchner, H., Schomburg, A., Schuler, A., Manns, M., Lopez-Hanninen, E., Duensing, S., Poliwoda, H., and Atzpodien, J. (1994). Cytokine-based biotherapy of gastrointestinal tumors. *Clin Investig* 72, 526-534.
- 331. Volkenandt, M., Wienecke, R., Koch, O.M., Buer, J., Probst, M., Atzpodien, J., Horikoshi, T., Danenberg, K., Danenberg, P., and Bertino, J.R. (1993). Conformational polymorphisms of cRNA of T-cell-receptor genes as a clone-specific molecular marker for cutaneous lymphoma. *J Invest Dermatol* 101, 514-516.